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Asthma treatment is challenging in older adults. To date, there is no evidence from research with 
older adults to support choosing the most appropriate add-on treatment for inadequately 
controlled asthma, despite using inhaled corticosteroids (ICS). We retrospectively investigated 
the comparative effectiveness, cardiovascular (CV) safety and costs associated with ICS + 
leukotriene receptor antagonists (ICS+LTRA) versus ICS + long acting beta agonists 
(ICS+LABA) treatments. We included asthmatic Medicare beneficiaries aged 66 and older, who 
continuously enrolled in Fee for Service Medicare with Part D coverage, and treated with 
ICS+LABA or ICS+LTRA in an exclusive manner.  
This dissertation work was organized into two major studies. Firstly, effectiveness and 
CV safety outcomes were compared between the two treatments. The augmented inverse 
propensity weighted estimator was used to determine the effect of LABA vs. LTRA add-on 
therapy on asthma exacerbations requiring inpatient, emergency, or outpatient care as well as CV 
events, adjusting for several co-variables. Our results showed that LTRA add-on treatment was 
associated with increased odds of asthma-related hospitalizations/emergency department visits 
(OR=1.4, p<0.001), and outpatient exacerbations requiring oral corticosteroids or antibiotics 
(OR=1.41, p<0.001) compared to LABA treatment. LTRA add-on therapy also showed lower 
effectiveness in controlling symptoms as indicated by greater utilization of short-acting beta 
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agonists (RR=1.58, p<0.001). On the other hand, LTRA add-on treatment was associated with 
lower odds of experiencing a CV event compared to LABA (OR=0.86, p=0.006).  
Secondly, multivariable regression models with nonparametric bootstrapped standard 
errors were employed to compare all-cause and asthma-related costs between the two treatment 
groups. The results showed that ICS+LTRA treatment was associated with increased asthma-
related costs compared to ICS+LABA. With a mean of 1.06 person-years follow up, adjusted 
asthma-related costs were $4,724 for ICS+LTRA group vs $2,939 for ICS+LABA group 
(p<0.001). Total all-cause costs were not significantly different between treatment groups 
($74,369 for ICS+LABA compared with $68,944 for ICS+LTRA (p=0.219)). Together, these 
findings provide new evidence specific to older adults to help health care providers weigh the 
risks and benefits of these add-on treatments. The economic evaluation conducted in this 
dissertation can enhance clinical decision-making and efficient evidence-based health practice in 
older adults. 
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1.0  INTRODUCTION  
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Asthma is common among older adults and causes great morbidity and mortality [1-3]. Asthma 
in older adults is more severe, less controlled and more likely to have higher costs than asthma in 
adulthood [4, 5]. Despite that, few studies have focused exclusively on measuring the 
effectiveness and safety of treatments in older adults with asthma. The fact that older adults are 
under-represented in clinical trials has led to a paucity of knowledge regarding the relative 
effectiveness, safety and costs of asthma treatments in this population [1, 6]. The evidence for 
treatment of asthma in older patients is mostly based on research conducted in younger adults or 
age-pooled populations [1]. 
LABA is the first line add-on treatment to inhaled corticosteroids among all ages [7]. 
LTRA is recommended as a second line add-on treatment. To date, there is no evidence from 
research focused on older adults to support choosing the most appropriate add-on treatment in 
patients with inadequately controlled asthma symptoms who are already using inhaled 
corticosteroids.   
The focus of this dissertation is on evaluating three important facets of health outcomes 
associated with the two most common add-on treatments (LTRA and LABA) in older adults with 
persistent asthma. Chapter 2 presents a review of the disease focusing on burden and treatment 
challenges in older adult patients. Further, Chapter 2 provides a review of the available literature 
and gaps that support the rationale for this dissertation. The specific research aims and 
hypotheses as well as the conceptual framework for the studies are presented in Chapter 3. The 
comparative effectiveness and CV safety of the two add-on treatments are investigated in 
Chapter 4 (study #1). Several indicators of asthma treatment effectiveness and CV safety were 
examined and compared between the two treatments, including: 1) asthma exacerbations 
requiring hospitalization or emergency department (ED) use; 2) asthma exacerbations treated in 
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an outpatient setting; 3) extent of use of short-acting beta agonists (SABA); 4) CV exacerbations 
requiring hospitalization or emergency department (ED) use; 5) changing the treatment which 
defined as adding or switching to the other add-on treatment; and 6) all-cause mortality.  Chapter 
5 (study #2) compares the economic outcomes associated with the two add-on treatments. 
Economic outcomes investigated in this study include all-cause costs (medical, pharmacy and 
total) and asthma related costs (medical, pharmacy and total). Finally, Chapter 6 summarizes the 
findings of the two studies, describes the implications and insights that the dissertation provides 
for informing health care-related decision-making, and summarizes the major limitations in this 
dissertation work with directions for future research to address these limitations. 
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2.0  BACKGROUND AND LITERATURE REVIEW 
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2.1 OVERVIEW OF ASTHMA 
2.1.1 Definition and Clinical Presentation  
Asthma is an inflammatory chronic lung disease that affects and narrows the airways, and 
causes recurrent episodes of breathlessness, wheezing, chest tightness, and coughing. These 
episodes are typically associated with airflow obstruction that is usually reversible spontaneously 
or with the treatment [7].  
Clinical presentation:  
Asthma presentation can vary from chronic daily symptoms to only intermittent 
symptoms with weeks, months, or years in between episodes. Chronic asthma is characterized by 
episodic dyspnea associated with wheezing, chest tightness, coughing (particularly at night), or a 
whistling sound when breathing. These symptoms often occur with exercise, stress or in response 
to allergens. Uncontrolled asthma can progress to an acute state featured by inflammation, 
airway edema, excessive accumulation of mucus, and severe bronchospasm. Severe asthma 
attack can result in intense airway narrowing that is poorly responsive to usual bronchodilator 
therapy and can become a life-threatening emergency [7-11].  
2.1.2 Epidemiology 
Asthma is a common respiratory chronic disease with more than 300 million people worldwide 
affected by the disease [12, 13]. The World Health Organization (WHO) has estimated that 15 
million disability-adjusted life-years are lost and 250,000 asthma deaths per year are reported 
6 
worldwide [14]. Asthma is one of the most commonly diagnosed chronic diseases in the US. It is 
estimated that asthma affects 5-10% of the US population, or about 23.4 million persons [15]. 
2.1.3 Pathophysiology  
Airflow limitation in asthma is recurrent and caused by a variety of changes in the airway as 
depicted in Figure 2-1 [11, 16-20]. These changes include: 
- Intermittent obstruction: The major characteristics of asthma include a variable degree of 
airflow obstruction that can be due to bronchospasm, edema, hyper-secretion and airway 
remodeling. Bronchoconstriction featured by airway smooth muscle contraction is mostly 
acute and allergen-induced as a consequence of immunoglobulin E-dependent mediator 
from mast cells that includes histamine, tryptase, leukotrienes, and prostaglandins. In 
addition, other stimuli for acute airflow obstruction including exercise, cold air, and 
irritants. 
- Airway inflammation: Inflammation and associated edema and mucus hyper-secretion 
contribute to airflow obstruction and bronchial reactivity. Mast cells, eosinophils, 
epithelial cells, macrophages, and activated T lymphocytes are the principal cells 
identified in airway. Structural changes including hypertrophy and hyperplasia of the 
airway smooth muscle can result from chronic inflammation. 
- Bronchial hyperresponsiveness, which is an exaggerated ability of the airways to narrow 
in response to a variety of stimuli. Inflammation acts as the major factor in determining 
the degree of airway hyperresponsiveness. Other contributing factors include 
dysfunctional neuroregulation and structural changes.  
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Figure 2-1 Pathophysiology of asthma. 
Adapted from: National Institutes of Health (2007). National Asthma Education and Prevention Program 
[11] 
 
2.1.4 Classification of Asthma 
Based on the symptoms, asthma can be classified into the following [11]: 
• Intermittent asthma: Symptoms occur on fewer than 2 days a week and do not interfere 
with normal activities. 
• Mild persistent asthma: Symptoms occur on more than 2 days a week but not every day, 
interfere with daily activities (minor) or occur at night 3-4 times a month.   
• Moderate persistent asthma: Symptoms occur daily, interfere with daily activities or 
occur at night more than 1 time a week, but do not happen every day. 
• Sever persistent asthma: Symptoms occur throughout the day, severely limit daily 
activities, or occur at night often or every night. 
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2.1.5 Treatment of Chronic Asthma 
Desired outcomes: The goals of treatment for chronic asthma are to 1) achieve good control of 
symptoms and maintain normal pulmonary function; 2) prevent troublesome symptoms; 3) 
maintain normal activity levels including exercise and other normal physical activities; 4) 
prevent recurrent exacerbations of asthma and minimize the need for emergency department 
visits or hospitalizations; 5) provide optimal pharmacotherapy with minimal or no adverse 
effects; and 6) improve quality of life [7, 16]. 
General approach [7, 11, 21, 22]:  
- Avoidance of triggers known to precipitate or worsen asthma  
- Quick relief medications include short-acting beta2-agonists, anticholinergics, and 
systemic corticosteroids 
- Long-term control medications include inhaled corticosteroids, inhaled long acting 
beta agonists, oral leukotriene receptor antagonists, oral theophylline, and systemic 
corticosteroids in patients with severe asthma 
 
 Non-pharmacologic treatment:  
This includes patient education of self-management skills, avoidance of known allergenic 
triggers, avoidance of dehydration and supplemental oxygen therapy in acute severe asthma. 
Patients should play an active role in their therapy. Patients must understand the role of long-
term control versus quick relief medications in their asthma treatment. Moreover, proper use of 
medication delivery devices should be continually evaluated. 
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 Pharmacologic treatment: 
Stepwize approach: in this approach, the dose and number of medications and frequency of 
administration are increased as necessary and decreased when possible (Figure 2-2).  
- Step one: As needed reliever inhaler.  
Intermittent asthma: Long-term control medications are not necessary, and patients 
should use a short-acting inhaled beta2-agonist to prevent or treat symptoms. 
- Step two: One low dose controller medication plus as needed reliever medication.  
Mild persistent asthma: Daily use of a low-dose inhaled corticosteroid is the preferred 
treatment in all age groups. Cromolyn, nedocromil, and leukotriene modifiers are 
alternatives for patients who cannot take inhaled corticosteroids. 
- Step three and four: One or two controllers plus as needed reliever medication.  
Moderate persistent asthma: The addition of a long-acting inhaled beta 2 agonist to low 
dose inhaled corticosteroids is the preferred treatment (step 3). Alternative is using 
medium-dose inhaled corticosteroids. Those with risks for severe exacerbations, the 
combination of a medium-dose inhaled corticosteroid plus a long-acting inhaled β2-
agonist may be preferred for asthma control (step four). 
- Step five and six: Two or more controllers plus as needed reliever medication:  
Severe persistent asthma: The treatment choice depends on selection in the prior step. 
Patients with severe persistent asthma should receive high dose inhaled corticosteroids 
and a long-acting inhaled beta2-agonist. If not well controlled, adding another add-on 
controller like a leukotriene receptor antagonists or theophylline is suggested as better 
alternative to starting systemic corticosteroids because of the significant adverse effects 
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seen with long-term therapy. Adding leukotriene receptor antagonists may permit dose 
reduction of inhaled corticosteroids in moderate and severe asthmatics and improve 
outcomes.  
All patients with chronic asthma should be prescribed a short-acting inhaled beta agonist to treat 
symptoms as needed. In addition, non-pharmacological strategies should be emphasized 
continuously. 
 
 
Figure 2-2 Stepwise approach for managing asthma in youths ≥ 12 years of age and 
adults. 
EIB, exercise-induced bronchospasm; ICS, inhaled corticosteroid; LABA, long-acting inhaled beta2- 
agonist; LTRA, leukotriene receptor antagonist; SABA, inhaled short-acting beta2-agonist. Adapted from 
National Asthma Education and Prevention Program Expert Panel Report 3: Guidelines for the Diagnosis 
and Management of Asthma 2007 [11]. 
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Main pharmacologic classes [11, 21, 22] 
Beta agonists:   
Mechanism of action: Beta 2-Adrenergic receptor stimulation activates adenyl cyclase, which 
produces an increase in intracellular cyclic AMP. This results in smooth muscle relaxation, mast 
cell membrane stabilization, and skeletal muscle stimulation. 
- Short acting beta agonists are the first treatment of choice for acute severe asthma. Used 
for treatment of intermittent episodes of bronchospasm. Example: Albuterol.  
- Long acting beta agonists: indicated as adjunctive long-term control for patients with 
symptoms who are already on low to medium doses of inhaled corticosteroids. Examples: 
Formoterol and Salmeterol. 
Corticosteroids: 
Mechanism of action: corticosteroids suppress airway inflammation primarily by decreasing 
inflammatory cytokines transcription and production e.g. interleukin (IL)-4 (IL-4), IL-13. ICS 
reverse the mucosal edema, decrease vascular permeability by vasoconstriction, and inhibit the 
release of pro-inflammatory leukotrienes. In addition, Corticosteroids increase the number of 
beta adrenergic receptors and improve receptor responsiveness to beta 2 adrenergic stimulation, 
reduce mucus production and hypersecretion, and prevent and reverse airway remodeling.  
- Inhaled corticosteroids are the most effective long-term control therapy for persistent 
asthma and the only therapy shown to reduce the risk of death from asthma. Examples: 
Fluticasone, Budesonide and Beclomethasone.  
- Systemic corticosteroids are indicated in acute severe asthma not responding completely 
to aggressive inhaled beta-2 agonists. Example: Prednisone. 
12 
Leukotriene Modifiers: 
Mechanism of action: leukotriene modifiers act by preventing the action of leukotrienes in the 
body. Leukotrienes are released from mast cells, basophils and eosinophils and causes airway 
constriction, increased mucus production, swelling and inflammation in the airways. They are 
recommended as an alternative to ICS when ICS cannot be used or as add-on treatment in asthma 
that is not completely controlled by an ICS. Examples: Zafirlukast and Montelukast acting by 
blocking leukotriene receptors; Zileuton acts by inhibiting leukotriene synthesis.   
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2.2 ASTHMA IN OLDER ADULTS 
2.2.1 Overview  
Older adults with asthma are characterized by distinct health care needs as well as distinct 
pathophysiology of the disease [23-27]. Compared to younger patients, asthma in older adults is 
less reversible and associated with features of airway remodeling that are not observed in 
younger ages [28-30]. Still, there are multiple unanswered questions about the underlying 
pathophysiology in older adults [30]. The frequent coexistence of comorbid conditions, poor 
recall and perception of symptoms, physical disability, depressive symptoms, reduced 
psychological and physical quality of life, low adherence and treatment side effects are the major 
factors making older adults population different from younger patients [1, 31-35]. Older adults 
have a high prevalence of multi-morbidities. In a recent study, older adults with asthma had a 
mean of 8.4 chronic comorbid conditions compared to 3.4 in younger adults [36]. Comorbid 
conditions impose substantial burdens on the older adults [37]. In addition, comorbid conditions 
contribute to poor asthma outcomes including impaired quality of life, unscheduled asthma care, 
emergency department visits, hospitalizations and fatality after asthma hospitalizations [2, 38-
41]. Comorbidities including chronic obstructive pulmonary disease (COPD), depression, 
obesity, gastroesophageal reflux disease, cardiac diseases and sleep apnea are frequently exist 
with asthma, and may potentially impact asthma outcomes in older adults [2]. Beside survival, 
quality of life (QoL) is of great concern and it is interactively related to treatment outcomes and 
adherence [26]. Treatment side effects can greatly affect QoL within this population. The 
incidence of drug-induced adverse effects in older adults is high, and adherence to therapeutic 
regimes is often poor [1, 42]. Thirty seven percent of respondents to qualitative survey of older 
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asthmatic adults in Australia were concerned about medication side effects. About 41% reported 
side effects from their medication including voice changes and a sore dry throat, and half of them 
reported tremor [24, 43]. Asthma management in older adults is challenging and patients’ 
response to pharmacological treatments might be different from younger ages [42, 44]. 
Treatment effectiveness and safety determined among younger cohorts may not be appropriately 
applied for older adult patients with a special concern of underestimating the safety facet of some 
treatments. As previous clinical trials have rarely focused on older adult patients [1, 6], further 
research is needed on treatment effectiveness and safety in controlling asthma and in the 
presence of co-morbidities in the older adult population.  
2.2.2 Epidemiology  
Asthma is frequent in the older adult population, with the prevalence estimated to be greater than 
10% [1]. It was estimated that around 15% of adults with asthma are 65 years of age or older 
[45]. However, the true prevalence of asthma in older adults is suggested to be much higher due 
to poor perception of symptoms and misdiagnosis with other conditions such as chronic 
obstructive pulmonary disease and gastroesophageal reflux disease [46-51]. Available data 
suggest that asthma burden in older adults is increasing both due to the high prevalence of 
asthma and the aging of the population [3, 52]. The population of older adults is expanding in 
USA; by 2030, an estimated 21% of the population will be 65 years of age or older [53]. In fact, 
the burden of asthma is more significant in the older adults than in younger patients. Asthma in 
older adults is associated with higher medical demands, worse outcomes and greater 
socioeconomic costs compared to younger adults [1, 2]. 
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2.2.3 Asthma Mortality, Morbidity and Economic Burden in Older Adults 
Older adults have greater asthma mortality compared to younger ages. More than 50% of asthma 
deaths occur among persons aged 65 years and older, and older asthmatics were shown to have a 
5- fold increased risk of overall mortality compared with younger adults (adjusted odds ratio, 
5.2; 95% CI, 4.0-6.9) [3, 54, 55]. Moreover, mortality rates in asthmatic older adults are 
increasing more rapidly than in younger ages (Figure 2-3) [54]. 
Asthma in older adults is more severe and uncontrolled than asthma in adulthood [4, 5, 
56]. Higher rates of hospital admission, longer length of hospital stay, higher number of 
medication prescriptions and higher number of emergency department visits contribute to the 
poor economic outcomes in older adult patients [52, 57]. Specifically, 54%, 35% and 7% of 
direct asthma related costs in older adult asthmatic patients account for hospital inpatient care, 
medications and outpatient care, respectively [52]. Second only to 0-4 age group, asthmatic older 
adult patients contribute to highest number of hospital discharges [54]. Few reports have focused 
primarily on measuring asthma costs in older adults. A study conducted in 1994-1995 showed 
that asthma direct costs were double in older adults asthmatics (average per year $1,490 vs. 
$773) than in younger adult asthmatic [52]. Obviously, such poor outcomes mandate further 
attention to find the contributing factors and the possible interventions needed to attain better 
clinical and economic outcomes.  
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Figure 2-3 Asthma mortality rates by age per million, age-adjusted to the 1970 standard 
million (adapted from [54]). 
2.2.4 Asthma Treatment in Older Adults; The Add-on Challenge  
Treatment guidelines for asthma in older adults are primarily based on clinical trials conducted in 
adult populations [1], in which older ages were systematically excluded as ineligible [6]. ICS 
started at a low doses, are recommended as initial therapy for patients with persistent asthma 
[33]. When asthma symptoms are not well-controlled on low dose ICS, it is recommended to 
increase the dose of ICS or to add another agent, such as LABA or LTRA [33]. In patients with 
high risk for steroid side effects (e.g., osteoporosis or glaucoma), it is preferable to add either 
LABA or LTRA agents [33, 44].  
The Global Initiative for Asthma (GINA) guidelines recommend LABA as the first line 
add-on treatment among all ages, and LTRA as the second-line add-on therapy [7]. These 
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guidelines acknowledge the fact that asthma treatments are still understudied in older adults. 
Combination of ICS and LABA treatments were shown to be an effective treatment [58, 59]. In a 
meta-analysis in which older adults were under-represented (patients aged 12 years or over), 
combination of ICS and LABA treatments improved lung function and symptoms, decreased 
rates of exacerbation and decreased the use of SABA compared to increased dose of inhaled 
steroid [59]. Similarly, ICS+LABA treatment has been shown to be more effective than 
ICS+LTRA in controlling asthma in populations mostly composed of non-older adult patients  
[60-63].  However, the overall pulmonary and CV safety of LABA for asthma is questioned in 
several studies [42, 64]. A growing concern is asthma-related morbidity and mortality associated 
with LABA when given with or without ICS [65-71]. In a meta-analysis of randomized, placebo-
controlled trials of >3 months conducted in age pooled populations, LABA increased 
exacerbations requiring hospitalization (OR are 2.6) and life-threatening exacerbations (OR 1.8) 
compared to placebo [70]. These effects were present even when LABA treatment was combined 
with ICS [71]. However, other studies conducted in adults showed a non-significant increase in 
asthma related hospitalizations with uncertain effect regarding asthma deaths [72, 73]. It was 
proposed that the development of tolerance to LABA broncho-protective effects over time is the 
main mechanism behind these poor asthma related outcomes [71]. This phenomenon was shown 
to increase with age and also is suggested to involve other unknown mechanisms [74].  
Another major concern regarding LABA agents in older adults is their CV safety [75, 
76]. In a large meta-analysis of placebo controlled clinical trials that compared LABA treatment 
to placebo in age pooled populations, LABA were shown to increase the risk for adverse 
cardiovascular events including arrhythmias, ischemia, hypertension, congestive heart failure and 
death (Figure 2-4) [76]. The inotropic and chronotropic effects of LABA are the major 
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suggested pathways for increasing arrhythmias, cardiomyopathy and myocardial ischemia. 
LABA can also cause electrolyte disturbances that contribute to arrhythmias [74]. Other side 
effects of LABA that are significant to the older adults patients and shown to be quality of life 
detrimental include tremor, tachycardia, hypokalemia and blood pressure changes [42, 76] 
Figure 2-5 summarize the suggested biological pathways behind LABA associated cardio and 
pulmonary adverse effects.  
 
 
Figure 2-4 Cardiovascular effects of beta agonist use. Adapted from [76]. 
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Figure 2-5 Suggested biological pathways behind LABA associated cardio and 
pulmonary adverse effects [77, 78]. 
 
As an alternative to LABA, LTRA treatment has been shown to be effective in 
controlling asthma symptoms when compared to placebo as monotherapy and when added as an 
adjunctive treatment among all ages [79-83]. Montelukast, as add-on therapy to ICS, was shown 
to improve clinical outcomes significantly as compared to ICS alone [79]. In a study of older 
adult population (more than 60-year old), montelukast, as add-on therapy to ICS, was shown to 
increase days without asthma symptoms, reduce days with beta-agonist use, and improve the 
mean asthma control test score significantly as compared to ICS alone [79]. In another study,  
after 4 weeks of using LTRA (zafirlukast), older adult patients demonstrated improvement in 
morning peak expiratory flow (PEF) and a decrease in symptoms compared to baseline [82]. 
Still, as the case with other asthma treatments, there are relatively few LTRA studies in older 
adults, and LTRA effectiveness needs to be further evaluated in a representative older adult 
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population and in comparison with other asthma treatments [44, 80]. In general, LTRA safety 
profiles are encouraging, particularly in older adults [44, 83, 84]. Interestingly, it was suggested 
that LTRA agents, beyond their actions in asthma, are promising in the secondary prevention of 
CV and cerebrovascular (CBV) diseases [85, 86]. The anti-inflammatory effect of LTRA 
treatment was suggested to inhibit the development of atherosclerosis, reduce intimal hyperplasia 
after vascular injury and exert a protective effect after cerebral ischemia and reperfusion [85]. In 
a nationwide population-based cohort of approximately 7 million persons, montelukast was 
associated with a lower risk (versus persons not taking montelukast) of recurrent stroke (HR, 
0.62; 95% CI, 0.38-0.99) accounting for age, sex, education level, and yearly income in 
asthmatic patients. Also, montelukast use was significantly associated with lower risk of 
recurrent myocardial infarction in male subjects (HR, 0.65; 95% CI, 0.43-0.99) [86]. This is of 
special importance particularly in older adult populations in which the CV and CBV diseases 
have a higher prevalence and contribute to substantial clinical and economic burden [87, 88]. 
Suggested biological pathways behind LTRA cardio-protective effect are depicted in Figure 2-6. 
In addition, LTRA have characteristics that make them potentially favored in older adult 
population, such as having few and mild side effects and simplicity of use; orally once or twice 
daily [44]. Further, there is no concern in the literature regarding the CV safety of LTRA therapy 
in adults or older adult population. Rare cases of acute hepatitis and Churg-Strauss syndrome 
have been described in older adult patients; but with uncertain relationship with age [83].  
The fact that older adult patients are under-represented in clinical trials generates a 
paucity of knowledge regarding the relative effectiveness, safety and costs of these add-on 
treatments in older adults. Both asthma and CV outcomes have not been compared directly 
between ICS+LABA and ICS+LTRA in representative older adult population.  
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Figure 2-6 Suggested biological pathways behind LTRA cardio-protective effect [85, 
86]. 
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2.2.5 ICS+LTRA versus ICS+LABA Direct Comparison in Non-older Adult Population 
Effectiveness: 
A considerable body of observational retrospective research conducted in non-older adult 
populations had suggested that LABA treatment is more effective as add-on treatment than 
LTRA treatment [61-63]. Tan et al explored asthma outcomes in patients aged 18 through 64 
years old, and they found that LTRA add-on treatment was associated with higher odds of 
inpatients or ED visits (OR = 1.40; CI=1.13-1.73), higher odds of OCS (OR=1.33; CI= 1.23-
1.44) and higher SABA utilization [63]. Another retrospective study showed that asthma 
exacerbations were more likely with ICS+ montelukast compared with ICS+ LABA in adults 
(18–56 years) initiating asthma controller (OR = 1.4, 1.2–1.6) [61]. Similarly, some relatively 
short term clinical trials showed that ICS+LABA is superior in improving lung function and 
controlling daily symptoms [60, 89, 90]. However, longer-term clinical trials showed evidence of 
non-inferiority of LTRA versus LABA add-on treatment [84]. A 52 week, double blind, 
multicentre trial including patients 15-72 years old showed that adding montelukast to ICS is at 
least as effective as adding salmeterol in preventing asthma exacerbations [91]. This non-
inferiority was also supported by a network meta-analysis shows that there is no significant 
difference in preventing severe asthma exacerbations between ICS+LABA and ICS+LTRA [92].  
Several studies have consistently shown lower SABA use in patients treated with 
ICS+LABA compared to ICS+LTRA [61-63, 93]. This is logical and expected since both LABA 
and SABA belong to the same family of beta 2 agonists with similar mechanism of action.  
Overall, data from mostly non-older adults based research still conflicting. However, the 
majority of evidence favored ICS+LABA as superior treatment in controlling asthma compared 
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to ICS+LTRA. Table 2-1 summarizes the available literature that compared effectiveness in 
controlling asthma between the two add-on treatments in younger adults or age pooled research.  
Table 2-1 Head to head asthma outcome comparisons between ICS+LABA and ICS+LTRA 
treated asthmatic adults. 
Outcomes Study ICS+LABA Age±SD (N) 
ICS+LTRA 
Age±SD (N) 
Relative 
effect Favor Design 
Asthma related 
inpatient visit  
or ED visit 
Stempel 
2002[62] 
40.5±16.3 
703 
30.9±19.8 
216 OR= 1.28  ICS+LABA
Retrospective 
cohort study; 
claims data 
Asthma related 
inpatient visit  
or ED visit 
Tan 2009 
[63] 
43±12 
23,549 
44±12 
1,065 OR= 1.40  ICS+LABA* 
Retrospective 
cohort study;  
claims data 
Asthma related 
inpatient visit  
or ED visit 
Lee 2010 
[61] 
39.30 +10.65 
13 608 
38.76 +10.69 
590 RR= 1.39 ICS+LABA* 
Retrospective 
cohort study; 
claims data 
Asthma related 
inpatient visit  
or ED visit 
Allen-
Ramey, 
2006 [93] 
28.3±16.6 
608 
27.9±15.9 
608 OR= 0.58 ICS+LTRA* 
Retrospective 
cohort study; 
data claims 
Asthma related 
inpatient visit 
Stempel 
2002 [62] 
40.5±16.3 
703 
30.9±19.8 
216 OR= 2.48  ICS+LABA
Retrospective 
cohort study; 
claims data 
Asthma related 
ED visit 
Stempel 
2002 [62] 
40.5±16.3 
703 
30.9±19.8 
216 OR= 1.28  ICS+LABA
Retrospective 
cohort study; 
claims data 
Use of OCSs Tan 2009 [63] 
43±12 
23,549 
44±12 
1,065 RR= 1.33 ICS+LABA* 
Retrospective 
cohort study; 
claims data 
Use of OCSs 
Allen-
Ramey, 
2006 [93] 
28.3±16.6 
608 
27.9±15.9 
608 OR=1.04  ICS+LABA
Retrospective 
cohort study; 
data claims 
Asthma related 
inpatient visit  
Bjermer 
2003 [91] 
41.0±13.7 
743 
41.2 ±13.6 
747 RR  = 0.71  ICS+LTRA
A 52 week, 
double blind, 
multicentre trial 
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Asthma related 
inpatient visit  
Ilowite 
2004 [94] 
38.1 (15–70) 
730 
39.0 (14–73) 
743 RR= 0.59  ICS+LTRA
A 48 weeks 
randomized, 
double-blind, 
double-dummy, 
multicenter 
study 
Asthma related 
ED visit 
Bjermer 
2003 [91] 
41.0±13.7 
743 
41.2±13.6 
747 RR= 0.99  ICS+LTRA
A 52 week, 
double blind, 
multicentre trial 
Asthma related 
ED visit 
Ilowite 
2004 [94] 
38.1 (15–70) 
730 
39.0 (14–73) 
743 RR=0.92  ICS+LTRA
A 48 weeks 
randomized, 
double-blind, 
double-dummy, 
multicenter 
study 
Use of oral, 
intramuscular, 
intravenous, or 
rectal 
corticosteroid 
Bjermer 
2003 [91] 
41.0±13.7 
743 
41.2±13.6 
747 RR= 1.10  ICS+LTRA
A 52 week, 
double blind, 
multicentre trial 
asthma 
exacerbations, 
which need 
OCS or 
Hospitalization 
for asthma. 
Price 2011 
[95] 
49.7±16.1 
182 
51.0±16.0 
170 OR= 1.02  ICS+LABA
Parallel, 
multicenter, 
pragmatic 2 
years trial 
Asthma 
exacerbation 
any severity 
Ringdal 
2003 [90] 
43±15.8 
356 
43±14.8 
369 
9.6 %  
CS/LABA 
14.6% 
ICS+LTRA 
ICS+LABA* 
Multinational, 
randomized, 
double-blind, 
double-dummy, 
parallel-group 
design, 12 weeks 
study 
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asthma 
exacerbation of 
either moderate 
or severe 
intensity 
Ringdal 
2003 [90] 
43±15.8 
356 
43±14.8 
369 
4.8 %  
ICS+LABA 
8.4% 
ICS+LTRA 
 ICS+LABA
Multinational, 
randomized, 
double-blind, 
double-dummy, 
parallel-group 
design, 12 weeks 
study 
Asthma 
exacerbation 
any severity 
Nelson 
2000 [89] 
40.2±14.4 
222 
43.0±13.7 
225 
2% 
ICS+LABA 
6% 
ICS+LTRA 
ICS+LABA* 
Multicenter, 
double-blind, 
double dummy, 
parallel-group, 
12-week study
≥6 SABA 
canisters 
Tan 2009 
[63] 
43±12 
23,549 
44±12 
1,065 OR=2.13 ICS+LABA* 
Retrospective 
cohort study;  
claims data 
≥6 SABA fills 
Lee 2010 
[61] 
39.30 +10.65 
13,608 
38.76 +10.69 
590 OR= 1.3  ICS+LABA
Retrospective 
cohort study ; 
claims data 
SABA use 
Allen-
Ramey, 
2006[93] 
28.3±16.6 
608 
27.9±15.9 
608 RR =1.33 ICS+LABA* 
Retrospective 
cohort study; 
data claims 
SABA use 
(Adjusted 
SABA canister 
refills) 
Stempel 
2002 [62] 
40.5±16.3 
703 
30.9±19.8 
216 
3.29 
ICS+LABA 
versus 4.45 
ICS+LTRA 
ICS+LABA* 
Retrospective 
cohort study; 
data claims 
* Statistically significant
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Cardiovascular safety: 
There is no published research designed specifically to measure cardiovascular events as a 
primary endpoint in asthma patients treated with ICS+LABA or ICS+LTRA. However, few 
studies have reported adverse CV outcomes. One meta-analysis of placebo controlled clinical 
trials found that LABA increased the risk for adverse cardiovascular events and death [76]. 
Another meta-analysis used mostly unpublished data from five studies with 5163 adults 
concluded that there is no statistically significant difference in the risk of cardiovascular events 
between ICS+LABA and ICS+LTRA (RR 1.09, 95% CI 0.77 to 1.53) [96]. Other studies showed 
that ICS+LTRA treatment was associated with less frequency of severe adverse events in general 
compared to ICS+LABA. A 52 week, double blind, multicentre trial including 15-72 year old 
patients showed that patients receiving salmeterol add-on treatment had a significantly higher 
incidence of drug related adverse events (10.0% v 6.3%, p = 0.01) and serious adverse 
experiences (7.4% v 4.6%, p = 0.022) compared with patients receiving montelukast add-on 
therapy [91]. The general safety of LTRA treatment was largely demonstrated in previous 
literature [83, 84]. Table 2-2 summarizes the comparative general safety and treatment 
satisfaction reported from adult cohorts. 
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Table 2-2 Head to head general safety and treatment satisfaction comparisons between 
ICS+LABA and ICS+LTRA treated asthmatic adults. 
Outcomes Study 
ICS+LABA 
Age±SD 
(N) 
ICS+LTRA 
Age±SD 
(N) 
Relative effect Favor Design 
Serious 
adverse 
events; No of 
patients (%) 
with >1 
serious 
adverse 
Bjermer 
2003 [91] 
41.0±13.7 
743 
41.2±13.6 
747 
5% 
ICS+LTRA 
7%ICS+LABA 
ICS+LTRA* 
A 52 week, 
double blind, 
multicentre 
trial 
Satisfaction 
with 
treatment 
Ringdal 
2003 [97] 
43±15.8 
356 
43±14.8 
369 
84% 
ICS+LTRA  
93% 
ICS+LABA 
ICS+LABA* 
Multinational, 
randomized, 
double-blind, 
double-
dummy, 
parallel-group 
design, 12 
weeks study 
Satisfaction 
with 
treatment 
Fish 2001 
[60] 
39.9±0.6 
476 
39.5±0.6 
472 
84% 
ICS+LABA 
79% 
ICS+LTRA 
ICS+LABA* 
Randomized, 
double-blind, 
double-
dummy, 
parallel-group, 
multicenter 
trials of 12-
week duration. 
* Statistically significant
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Economic outcomes 
As for effectiveness and safety outcomes, economic burdens associated with these add-on 
treatments were not compared particularly in older adult populations. A large body of research in 
the non-older adult population consistently showed that patients receiving ICS+ LTRA incur 
higher asthma related costs as compared with patients receiving ICS+LABA [61-63].  
Tan et al showed, in their retrospective study, that the total asthma related annual costs in 
ICS+LTRA treated group was 38% higher (p<0.001) than those for ICS+LABA group [63]. 
Similarly, Lee et al reported higher adjusted mean total asthma-related costs in patients treated 
with ICS+LTRA compared to ICS/LABA patients ($1223 vs. $873 per year) [61]. Pharmacy 
costs were a major driver of asthma expenditures and were significantly higher in patients treated 
with ICS+LTRA compared to ICS+LABA ($987 vs $606, respectively) [62]. Very few studies 
have evaluated all-cause costs in asthmatic adults. Stempel and coworkers showed that non-older 
adult patients treated with ICS+LABA incurred significantly lower total all-cause cost compared 
with ICS+LTRA ($3466 ICS+LABA versus $4346 ICS+LTRA). Another study evaluated total 
all-cause costs incurred by asthmatic patients treated with different asthma controllers found that 
compared to ICS only group as a reference, ICS+LTRA treated patients incurred $618 higher all-
cause costs whereas ICS+LABA treated patients incurred $1811 higher all-cause costs 
(compared to ICS alone) [98]. The difference in annual costs between the two add-on treatments 
was mainly due to lower non-asthma costs associated with ICS+LTRA. One potential 
explanation for such observation may be that LTRA are safer and more compatible with other 
heath conditions. However, total health care costs were not compared directly between the two 
add-on treatments. Table 2-3 summarizes available studies that compared economic outcomes 
between ICS+LABA and ICS+LTRA treated asthmatic adults. 
29 
Table 2-3 Head to head economic outcome comparisons between ICS+LABA and ICS+LTRA 
in adults. 
Outcomes Study ICS+LABA Age±SD (N) 
ICS+LTRA 
Age±SD (N) 
Relative  
effect Favor Design 
Annual total 
asthma-
related cost 
Stempel 
2002 [62] 
40.5±16.3 
703 
30.9±19.8   
216 
$952 
ICS+LABA 
versus 
$1552 
ICS+LTRA 
ICS+LABA* 
Retrospective 
cohort study; 
claims data 
Annual total 
asthma-
related cost 
Tan 2009 
[63] 
43±12  
23,549 
44±12  
1,065 
1226  
ICS+LABA 
1687 
ICS+LTRA 
ICS+LABA* 
Retrospective 
cohort study;  
claims data 
Annual total 
asthma-
related cost 
Lee 2010 
[61] 
39.30 +10.65 
13,608 
38.76 +10.69 
590 
873 
ICS+LABA 
versus 
$1223 
ICS+LTRA 
ICS+LABA* 
Retrospective 
cohort study; 
claims data 
Annual total 
asthma-
related cost 
(1st year 
initiation) 
Balkrishnan 
2005 [99] 
24.0±18.2    
97 
22.0±19.5    
101 
2224.60 
(4326.01) 
ICS+LABA 
1695.44 
(3538.50) 
ICS+LTRA 
 ICS+LTRA
Retrospective 
cohort study; 
claims data 
Annual total 
asthma-
related cost 
(2nd year  
after 
initiation) 
Balkrishnan 
2005 [99] 
24.0±18.2    
97 
22.0±19.5    
101 
2205.43 
(4155.40) 
ICS+LABA 
1911.29 
(4289.93) 
ICS+LTRA 
 ICS+LTRA
Retrospective 
cohort study; 
claims data 
Annual 
asthma-
related 
pharmacy 
Stempel 
2002 [62] 
40.5±16.3 
703 
30.9±19.8   
216 
$606 
ICS+LABA 
versus $987 
ICS+LTRA 
ICS+LABA* 
Retrospective 
cohort study; 
claims ata 
Annual total 
health care 
costs 
Stempel 
2002 [62] 
40.5±16.3 
703 
30.9±19.8   
216 
$3466 
ICS+LABA 
versus 
$4346 
ICS+LTRA 
ICS+LABA* 
Retrospective 
cohort study; 
claims data 
Annual total 
health care 
costs 
(unadjusted 
mean) 
Zeiger 2008 
[98] 
47.1±19.9 
8,125 
33.8±23.5 
1,235 
$5414 
ICS+LABA 
$4478 
ICS+LTRA 
 ICS+LTRA
Retrospective 
cohort study, 
claims data 
* Statistically significant
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3.0  RESEARCH SUMMARY, HYPOTHESIS, OBJECTIVES AND CONCEPTUAL 
MODEL  
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3.1 HYPOTHESIS AND SPESIFIC AIMS 
Older adult patients with asthma experience poor health outcomes and contribute a great 
economic and health burden to society. Guidelines recommend LABA as the first line add-on 
treatment in asthmatic patients. Serious pulmonary and CV concerns were raised in the literature 
regarding the use of LABA agents in asthmatic patients. These concerns emerged from general 
population research with evidence of a potentially more serious problem among older adults as 
previously described. Very limited research focuses exclusively on measuring the effectiveness 
and safety of LABA treatment for older adults with asthma. An alternative to LABA add-on 
therapy is LTRA which is potentially a much safer treatment with promising benefits in older 
adults. Yet, as the case with LABA, LTRA agents are understudied in older adults.  
The main objective of this dissertation work was to compare the effectiveness in 
controlling asthma, cardiovascular safety and costs associated with ICS+LTRA versus 
ICS+LABA treatments in older patients with asthma. We used Medicare fee for service data for 
two consecutive years (2009-2010) to test the following specific aims and hypotheses guiding 
the work: 
Aim 1: To compare asthma related outcomes associated with LTRA versus LABA 
add-on treatments in older adults with asthma.  
Hypothesis 1: Older adult patients treated with LABA add-on therapy have lower 
likelihood of asthma related exacerbations compared with those treated with LTRA add-on 
treatment. 
 
Aim 2: To compare the CV related exacerbations associated with LTRA versus 
LABA add-on treatments in older adults with asthma. 
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Hypothesis 2: Older adult patients treated with LTRA add-on treatment have lower 
likelihood of CV related exacerbations compared with those treated with LABA add-on 
treatment.  
Aim 3: To compare expenditures incurred by patients treated with LTRA versus 
LABA add-on treatments.  
Hypothesis 3: Using LTRA add-on treatment is associated with higher asthma related 
costs but with lower all-cause costs compared with LABA. 
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3.2 CONCEPTUAL MODEL 
This dissertation was guided by the conceptual model depicted in Figure 3-1. The conceptual 
model is derived from the Andersen behavioral model of health services utilization as a 
theoretical framework to assess predisposing, enabling, and need based factors that will likely 
affect health care utilization and outcomes [100]. The Andersen behavioral model of health 
services utilization suggests that health service use is a function of 3 main elements: 
predisposing, enabling, and need factors. Predisposing factors are those factors enhance the 
likelihood of using health services, and include demographic variables, socioeconomic status, 
attitudes, and beliefs. Enabling factors include factors such as the individual’s income, health 
insurance, and access to different health care resources. Finally, medical need factors include 
individual’s perceived health care need and illness experience as well as professional 
assessments of their health status and need for medical care [101, 102]. 
In Chapter 4 (study #1), treatment effects on asthma exacerbations, SABA use, CV 
exacerbations, all-cause mortality and treatment change were examined using the augmented 
inverse propensity weighted (AIPW) estimator accounting for predisposing, enabling, and need 
based factors as shown in Figure 3-1. In Chapter 5 (study #2), treatment effects on all-cause 
health care expenditures and asthma related expenditures were examined using nonparametric 
bootstrapping models accounting for predisposing, enabling, and need based factors as shown in 
Figure 3-1.  
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Figure 3-1 Dissertation conceptual model 
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4.0  ANTI-LEUKOTRIENE AGENTS VERSUS LONG ACTING BETA AGONIST IN 
OLDER ADULTS WITH PERSISTENT ASTHMA: A COMPARISON OF ADD-ON 
THERAPIES  
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4.1 ABSTRACT 
Asthma treatment guidelines recommend LABA over LTRA as the first-line add-on therapy 
when inhaled corticosteroids fail to achieve adequate asthma control. However, older adults were 
excluded from asthma trials and there is no conclusive evidence regarding the comparative 
effectiveness and safety of these agents in older adults. The safety profile of LABA in older 
adults may differ from that in younger adults due to a higher baseline risk of CV events. Thus, 
this study sought to compare the effectiveness and cardiovascular safety of LABA versus LTRA 
add-on treatments in older patients with asthma.  
This retrospective cohort study was conducted using Medicare claims and enrollment 
data for 2009-2010. We included asthmatic patients aged 66 years or older who were 
continuously enrolled in Fee for Service (FFS) Medicare with Part D coverage. We followed 
patients who were exclusively treated with each add-on treatment; in the primary analyses, 
patients were censored if they switched to or added the other treatment. The augmented inverse 
propensity weighted (AIPW) estimator was used to determine the effect of LABA vs. LTRA 
add-on therapy on asthma exacerbations requiring inpatient, emergency, or outpatient care as 
well as CV events, adjusting for demographics, comorbidities, and county level health care 
access variables.   
The primary analysis included 14,702 patients, of whom 12,940 were treated with 
ICS+LABA and 1,762 were treated with ICS+LTRA. Our results showed that LTRA add-on 
treatment was associated with increased odds of asthma-related hospitalizations/ED visits 
(OR=1.4, p<0.001), as well as outpatient exacerbations requiring oral corticosteroids or 
antibiotics (OR=1.41, p<0.001) compared to LABA treatment. LTRA add-on therapy also 
showed lower effectiveness in preventing acute symptoms as indicated by greater utilization of 
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SABA (RR=1.58, p<0.001). On the other hand, LTRA add-on treatment was associated with 
lower odds of experiencing a CV event compared to LABA (OR=0.86, p=0.006).  
Collectively, this study provides new evidence specific to older patients to help health 
care providers weigh the risks and benefits of these add-on treatments in older adults. Further 
subgroup analysis is needed to personalize asthma treatments in this higher-risk population. 
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4.2 INTRODUCTION 
Asthma is a common respiratory chronic disease that affects all ages worldwide [12]. It was 
estimated that around 15% of adults with asthma are 65 years of age or older [45].  In fact, 
asthma is frequent in the older adult population, with prevalence estimated to be greater than 
10% [1]. Because the older adult population in the U.S. continues to expand [53], optimizing 
asthma care for this population is critical. The burden of asthma is more significant in older 
adults than in the younger patients, with higher mortality, risk of hospitalization, and medical 
costs. Approximately, 50% of asthma deaths occur among persons aged 65 years and older [54]. 
Indeed, asthma in older adults tends to be more sever and uncontrolled than in adulthood [56]. 
Higher rates of hospital admission, longer length of hospital stay, greater medication use, and 
higher number of emergency department visits also contribute to higher economic burden of 
asthma in older adult patients [4, 5, 52]. Second only to the 0-4 year age group, asthmatic older 
adults contribute to highest number of hospital discharges [54]. Despite this, most studies of 
asthma therapies are focused on young adults. Very limited information exists on the use and 
outcomes of asthma therapies in older adults. In part, this is attributable to the systematic 
exclusion of older age groups from clinical trials [1, 6]. 
When asthma symptoms are not well-controlled on low dose ICS, it is recommended to 
add another agent, such as a LABA or LTRA. The Global Initiative for Asthma (GINA) 
guidelines recommend LABA as a first line add-on treatment among all ages, and LTRA as a 
second-line add-on therapy [7]. These guidelines acknowledge the fact that asthma treatments 
are still understudied in older adults. ICS+LABA treatment has been shown to be more effective 
than ICS+LTRA in controlling asthma in populations mostly composed of non-older adult 
patients [60-63]. However, the overall safety of LABA for asthma is questioned in several 
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studies [42, 64, 75, 76]. A growing concern is asthma-related morbidity and mortality associated 
with LABA when given with or without ICS [65-71]. Another major concern regarding LABA 
agents is their CV safety with an evidence of increased risks of major CV events including 
arrhythmias, ischemia, hypertension, congestive heart failure and death [75, 76]. Both asthma 
and CV concerns associated with LABA were raised from research in non-older adults or age 
pooled populations.  
As an alternative to LABA, LTRA treatment has been shown to be effective in 
controlling asthma symptoms when compared to placebo as monotherapy and when added as an 
adjunctive treatment among all ages [79-83]. Still, as the case with other asthma treatments, 
LTRA still understudied in older adults [44, 80]. In general, LTRA safety profiles are 
encouraging, particularly in older adults [44, 83, 84]. Interestingly, it was suggested that LTRA 
agents, beyond their actions in asthma, are promising in the secondary prevention of CV and 
cerebrovascular (CBV) diseases [85, 86]. This is of special importance particularly in older adult 
populations in which the CV and CBV diseases have a high prevalence and contribute to 
substantial clinical and economic burden [87, 88].  
Both asthma and CV outcomes have not been compared directly between ICS+LABA 
and ICS+LTRA in representative older adult population. The objective of this chapter was to 
compare the effectiveness in controlling asthma and cardiovascular safety of LABA versus 
LTRA add-on treatments in older patients with asthma. 
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4.3 METHODS 
4.3.1 Data Source 
The data source for this study consisted of 2009-2010 Medicare fee-for-service (FFS) medical 
claims (Parts A and B), Part D prescription drug event (PDE) data, and Beneficiary Summary 
Files (BSF) obtained from the Centers for Medicare and Medicaid Services (CMS) for a 10% 
random sample of beneficiaries continuously enrolled in Parts A, B, and D in 2009. The Part D 
prescription drug event data, MedPAR file, outpatient file, and carrier/professional services file 
provided information on asthma treatment exposures, outcomes, and covariates. Further, the 
beneficiary summary files were used to extract information on demographics, beneficiary 
entitlement and enrollment status, date of death, and comorbidities.  
4.3.2 Primary Study Design 
This study used a retrospective cohort design in which two treatment groups were identified: 1) 
exclusive users of ICS + LABA, and 2) exclusive users of ICS + LTRA. To be included, each 
patient was required to have at least 4 months of “wash-in” to eliminate any residual effect from 
prior use of the other add-on therapies that could potentially confound results. Patients were 
followed starting on the date of the first prescription for the add-on treatment after the 4 months 
wash in period. Patients were censored if they died or switched to or added the other add-on 
treatment (Figure 4-1).  
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Figure 4-1 Primary analyses design 
Follow up periods start on the date of the first prescription for the add-on treatment after the 4 months 
wash in period. Follow up periods end if died or switched to or added the other add-on treatment. 
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4.3.3 Sample  
Sample population consists of beneficiaries 65 years old or more as of Jan 1 2009 and 
continuously enrolled in FFS Medicare Parts A and B with Part D coverage from Jan-1 2009 to 
Dec-31-2010 (n= 1,160,380). The sample was then limited to those who met criteria of having an 
asthma diagnosis as of Jan 1 2009, as per the CMS Chronic Conditions Data Warehouse’s 
algorithm for detecting asthma in FFS Medicare beneficiaries (n= 128,928) [103, 104]. 
According to this validated algorithm, asthma diagnosis was identified by at least 1 inpatient, 
skilled nursing facility (SNF), home health agency (HHA) claim, or 2 hospital outpatient (HOP) 
or carrier claims defined by the International Classification of Diseases, Ninth Revision, Clinical 
Modification (ICD-9-CM) codes for asthma (493.XX). The sample was further limited to 
beneficiaries who were treated with at least one asthma controller medication, including ICS, 
LTRA, and/or LABA over 2009-2010 (n=56,300). Among these patients, only those who met the 
above wash-in criteria for being treated with ICS+LABA or ICS+LTRA in an exclusive manner 
over 2009-2010 years were included. Patients whose ages were less than 66 years as of Jan 2009 
were excluded to make sure that all patients had enough periods (at least one year) of medical 
claims to capture an accurate asthma diagnosis. Finally, individuals living in Europe and 
Philippines were excluded, due to lack of availability of important geographic covariates in the 
Area Resource File (described below). 
4.3.4 Outcomes 
Several indicators of asthma treatment effectiveness were examined, including: 1) asthma 
exacerbations requiring hospitalization or ED use; 2) asthma exacerbations treated in an 
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outpatient setting; and 3) extent of use of short-acting beta agonists (SABA).  Hospitalizations 
were identified from the MedPAR file and were considered asthma-related if the primary or 
secondary diagnosis ICD-9-CM code of these events was 493.XX [61, 98]. ED visits were 
identified in MedPAR and outpatient facility files using an established method [105] and were 
considered asthma-related if the primary or secondary diagnosis code was (493.XX). Asthma 
exacerbations treated in an outpatient setting were defined as face-to-face outpatient physician 
visits in the carrier file (identified through Current Procedural Terminology (CPT) codes) 
associated with a primary or secondary asthma diagnosis code and a PDE record for an antibiotic 
or oral corticosteroid (OCS) on the same day or within the next 7 days [106].  Finally, the extent 
of use of SABA (an indicator of effectiveness in preventing daily symptoms of asthma) was 
operationalized as the count of SABA prescriptions during the follow up period [107]. Part D 
event files were searched for SABA, OCS and antibiotics using national drug codes NDC 
(provided by the Healthcare Effectiveness Data and Information Set (HEDIS)). 
The measure of CV safety consisted of any CV-related hospitalization or ED visit during 
the follow up period.  Hospitalizations and ED visits were identified as CV related events if the 
primary or secondary diagnosis ICD-9-CM codes were (410.XX–414.XX) for ischemic heart 
disease, (427.XX) for cardiac dysrhythmias, (428.XX) for heart failure, (401.XX–405.XX) for 
hypertensive disease and (430.XX–438.XX) for cerebrovascular diseases.  
All-cause death was identified using date of death in The Master Beneficiary Summary 
File Base segment. 
Finally, switching to or adding the other add-on treatment after at least 6 months on the 
original treatment was considered and measured as treatment change. Such treatment change 
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might indicate poor effectiveness in controlling asthma and/or poor tolerance for side effects or 
other safety issues with the treatment.  
4.3.5 Covariates   
Several control variables were constructed to account for differences in baseline patient 
demographics, comorbidities, county level health access variables and other variables that might 
affect both treatment choice and outcomes. We obtained the following data from the Beneficiary 
Summary Files: patient ages were calculated as of Jan-1-2009, patient race/ethnicity (non-
Hispanic White, Black, Hispanic or others), state of residence, gender, enrollment in the low-
income subsidy, disability indicator, asthma duration since the first diagnosis in Medicare data 
and comorbid conditions. Many pre-existing comorbid conditions were adjusted for in our 
models including chronic obstructive pulmonary disease (COPD), cardiovascular disease, kidney 
diseases, depression, cancers and others. The first diagnosis for these conditions was required to 
occur before the date of starting patient follows up. Prescriber characteristics including number 
of unique prescribers of asthma medications as well as the specialty of the prescriber who 
accounted for the majority of asthma prescriptions were formulated using part D prescriber 
characteristics file. Part D data were also utilized to capture ICS strength at the date of starting 
follow up for each patient as a proxy for ICS dose and asthma severity.  Also, beta blockers were 
accounted for in the analysis because these medications may affect both asthma and CV 
outcomes [108].  Outpatient doctor visits in the “wash-in” period were also measured since 
higher outpatient visits might lead to higher admissions. Medicare data were linked to Health 
Resource and Services Administration’s (HRSA) Area Resource File (ARF) using zip codes to 
characterize some county level health care access variables including numbers for primary care 
45 
physicians, medical specialty physicians, allergy immunology specialty, CV specialty, 
pulmonary specialty, emergency medicine specialty, preventive medicine specialty, hospitals 
number and hospitals with emergency department. These variables were calculated as the 
number per 10,000 older adult residents for each county. County level rurality/urbanicity, 
average household size and percent below poverty variables were also extracted.  
4.3.6 Statistical Analysis 
Primary analysis: Treatment effects (Augmented inverse propensity weighting models): 
All analyses were conducted in Stata v13 ((StataCorp. 2013. Stata Statistical Software: Release 
13. College Station, TX: StataCorp LP).  As differences in patient and clinical characteristics at 
baseline would have the potential to bias results, propensity scores (PS) methodology was 
applied to balance treatment groups on potential confounders [109]. Augmented inverse 
propensity weighting with binary outcomes was utilized to obtain the adjusted probabilities for 
asthma and CV exacerbations, all-cause death and treatment change [110]. This method was 
used with count outcomes to obtain adjusted predicted rates for SABA fills. Odd ratios and rate 
ratios were calculated based on the adjusted predicted probabilities and rates produced by the 
augmented inverse propensity weighting estimator. The differing lengths of follow-up time 
across patients were addressed by adjusting for the natural log of person-years. These models 
included all covariates as defined above.  
 Augmented inverse propensity weighting estimator models both the outcome and the 
treatment probability and is considered “doubly robust” since only one of the two models must 
be correctly specified to consistently estimate the treatment effects [110]. 
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Main analyses were repeated after excluding patients who died assuming these patients 
are sicker than the other population.  
Imputation for missing values was implemented using the hotdeck procedure, where 
missing values were replaced by random values from the same variable, using the Schonlau 
implementation for the Stata software [111].  Hotdeck imputation has the advantage of being 
simple to use and preserves the distributional characteristics of the variable [112].  
Treatment effect modification by major comorbidities: 
Interactions between the treatment and the presence of preexisting CVD, as well as between 
treatment and the presence of COPD, were analyzed for each outcome model using the 
likelihood ratio test after estimating regression models with and without the interaction. 
Stratified analyses were performed for the outcome models in which interactions contributed 
significantly to treatment effect. Two analyses were conducted to test treatment interaction with 
preexisting CVD. In the first analysis, preexisting CVDs were defined as having a prior 
diagnosis of ischemic heart disease, acute myocardial infarction, congestive heart failure (CHF), 
atrial fibrillation (AF) and/or stroke/transient ischemic attack, as per established CMS Chronic 
Conditions Data Warehouse’s algorithms [103]. In the second analysis, preexisting CVD status 
were further categorized into three levels: having no preexisting CVD; having preexisting 
ischemic heart disease, acute myocardial infarction, or stroke/transient ischemic attack (ischemic 
diseases); and having congestive heart failure or atrial fibrillation (CHF/AF diseases) since both 
conditions share common risk factors, frequently coexist and each predisposes to the other [113]. 
In both analyses, patients with hypertension alone, without any other CVD, were assumed to be 
relatively stable and were included in the non CVD strata. 
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The effect of LABA add-on strengths (as a proxy for LABA dose): 
This analysis sought to investigate the effect of LABA add-on strength on all outcomes 
investigated in the primary analysis. LTRA treatment strengths were not different across the 
patients and so were not categorized. The main explanatory variable in this analysis was a three 
level treatment variable; 0= LTRA add-on, 1= LABA low strength add-on, and 2= LABA 
medium-high strength add-on. LABA strengths were measured at the first LABA prescription 
after the 4 months wash-in period. Multivariable logistic regression models were constructed and 
adjusted for all covariates as measured above.  
Sensitivity analysis 1: incident user design:  
In this design, only those new initiators of either LTRA or LABA add-on treatments (incident 
users) were included. Incident users were defined as those who used only ICS in the 3 months 
preceding the initiation of add-on therapy (LTRA or LABA). Patients were followed for the 
same outcomes in the primary analysis after the index date, which was defined as the date of the 
first pharmacy claim for either treatments (LTRA or LABA add-on) (Figure 4-2). Multivariable 
logistic regression/ Poisson regression were used and were adjusted for all covariates as mentioned above 
(baseline outpatient doctor visits were measured in the 3 months pre-index period). Patient 
characteristic and baseline variables were compared between treatment groups using unadjusted 
bi-variable tests (chi-square for categorical variables and t-test for continuous variables). 
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Figure 4-2 Incident users design  
Patients were required to have at least 3 months of ICS only prescriptions (without LABA or 
LTRA) 
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Sensitivity analysis 2: discontinuation design:  
In this analysis, patients’ fills were followed to exclude periods of no treatment supply based on 
‘days supply’ field in Medicare part D event file. Outcomes were followed only during the 
periods in which treatments were continuously available for patients as indicated by their fills. 
Accordingly, patients were censored once they had more than 30 days without treatment supply 
for either the ICS or the add-on treatment (treatment discontinuation) (Figure 4-3). All primary 
and sensitivity analyses mentioned above were repeated after applying the discontinuation 
design. 
 
 
Figure 4-3 Discontinuation design 
Patient prescriptions were followed and patients were censored once they were running out of either ICS 
or the add-on treatment for more than 30 days.  Each arrow represents a prescription.  
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4.4 RESULTS 
4.4.1 Patient Characteristics/Baseline Comparisons 
A total of 14,702 patients met the inclusion criteria, of whom 1,762 were receiving ICS+LTRA 
and 12,940 were receiving ICS+LABA in an exclusive manner. Table 4-1 compares all patient 
characteristic and baseline variables between treatment groups using unadjusted bi-variable tests 
(chi-square for categorical variables and t-test for continuous variables). Overall, patients 
averaged 76.5 years of age; 72% were female and 78% were non-hispanic whites. The 
ICS+LABA group generally had greater co-morbidities, with a higher prevalence of ischemic 
heart disease, congestive heart failure, atrial fibrillation, cerebrovascular disease, COPD, 
diabetes and other comorbidities. The most common co-morbid conditions (among the whole 
sample) were hypertension (91%), hyperlipidemia (83%), cataract (77.8) and COPD (77.7%). 
The average number of comorbid chronic diseases per patient was 9 across the whole sample; 9 
for ICS+LABA group and 8 for ICS+LTRA group. 
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Table 4-1 Study population characteristics by total and asthma add-on medication group 
  Total sample             n= 14,702 (%) 
LABA add-on        
n= 12,940 (%) 
LTRA add-on        
n= 1,762 (%) 
p 
value* 
Age     
65-70 2,883      (29.6) 2,495      (19.3) 388      (22.0) 0.008 
70-75 3,967      (27.0) 3,472      (26.8) 495      (28.1)  
75-80 3,478      (23.6) 3,097      (23.9) 381      (21.6)  
80+ 4,374      (29.8) 3,876      (30.0) 498      (28.3)  
Female gender 10,614    (72.2) 9,225      (71.3) 1,389   (78.8) <0.001 
Race     
Non-Hispanic     
white 11,423     (77.8) 10,086    (78.0) 1,337  (75.9) <0.001 
Black 1,293       (8.8) 1,148      (8.9) 145     (8.2)  
Hispanic 1,234       (8.4) 1,083      (8.4) 151     (8.6)  
Others 738          (5.0) 610         (4.7) 128     (7.3)  
Geographic region     
Northeast 3,192       (21.7) 2,748      (21.2) 444     (25.2) 0.001 
Midwest  3,317      (22.6) 2,910      (22.5) 407     (23.1)  
South 5,323       (36.2) 4,728      (36.5) 595     (33.8)  
West 2,868       (19.5) 2,553     (19.7) 315     (19.1)  
Asthma duration     
<6 months 781          (5.3) 726        (5.6) 55       (3.1) <0.001 
6-12 months 944         (6.4) 854        (6.6) 90       (5.1)  
1-2 years 1,682      (11.4) 1,496     (11.6) 186     (10.6)  
>2 years 11,295    (76.8) 9,864     (76.2) 1,431  (81.2)  
Disability 2,495      (17.0) 2,212     (17.1) 283     (16.1) 0.278 
Major prescriber 
specialty asthma drugs     
           Asthma 2,893      (19.7) 2,521     (19.5) 372      (21.1)  0.081 
General 9,360      (63.7) 8,230     (63.6) 1,130    (64.1)  
Non-physician 1,019      (6.9) 907        (7.0) 112       (6.4)  
Others 1,430      (9.7) 1,282     (9.9) 148       (8.4)  
Rural Urban     
Metro 11,471    (78.6) 10,108    (78.7) 1,363    (78.2) 0.909 
Urban 2,715      (18.6) 2,386      (18.6) 329        (18.9)  
Rural 404          (2.8) 354         (2.8) 50          (2.9)  
Low income enrollment 6,718      (45.7) 5,833      (45.1) 885        (50.1) <0.001 
Using beta blockers 5,863      (49.9) 5,265      (40.7) 598        (33.9) <0.001 
Medium to high ICS 
strength at index 
prescription 
11,223   (76.3) 10,114    (78.2) 1,109     (62.9) <0.001 
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Outpatients physician 
visits in the 4 months 
wash in period Means 
(SE) 
4.7        (0.033) 4.72       (0.035) 4.42      (0.097) <0.001 
Number of unique asthma 
prescribers Mean (SE) 1.5        (0.006) 1.4        (0.007) 1.7       (0.020) <0.001 
Study population Comorbidities 
Alzheimer 2,638    (17.9) 2,321   (17.9) 317       (18.0) 0.956 
Acute myocardial 
infarction 1,068     (7.3) 1,001   (7.7) 67          (3.8) <0.001 
Anemia 9,974     (67.8)  8,848   (68.4) 1,126     (63.9) <0.001 
Atrial fibrillation 2,990     (20.3) 2,688   (20.8) 302        (17.1) <0.001 
Cancers (other than lung 
cancer) 2,260     (15.4) 2,023    (15.6) 237        (13.5) 0.017 
Cataract 11,440   (77.8) 10,052  (77.7) 1,388    (78.8) 0.3 
Chronic kidney disease 
(CKD)      
No CKD 10,468   (71.2) 9,087      (70.2) 1,381        (78.4) <0.001 
CKD, no ESRD 4,109     (28.0) 3,737      (28.9) 372           (21.1) <0.001 
ESRD 125        (0.85) 116         (0.9) 9               (0.5) <0.001 
Chronic obstructive 
pulmonary disease 11,422  (77.7) 10,210    (78.9) 1,212       (68.8) <0.001 
Congestive heart failure 7,556    (51.4) 6,783      (52.4) 773          (43.9) <0.001 
Depression 6,316     (43.0) 5,638      (43.6) 678          (38.5) <0.001 
Diabetes 6,683     (45.5) 5,949      (46) 734         (41.7) 0.001 
Glaucoma 3,907    (26.6) 3,434      (26.5) 473         (26.8) 0.785 
Hip fracture 732        (5.0) 661          (5.1) 71            (4.0) 0.051 
Hyperlipidemia 12,265  (83.4) 10,813    (83.6) 1,452      (82.4) 0.221 
Benign Prostatic 
Hyperplasia 2,313    (15.7) 2,104      (16.3) 209         (11.9) <0.001 
Hypertension 13,378 (91.0) 11,815    (91.3) 1,563      (88.7) <0.001 
Hypothyroidism 3,978   (27.1) 3,523      (27.2) 455         (25.8) 0.214 
Ischemic heart 10,069 (68.5) 8,999      (69.5) 1,070     (60.7) <0.001 
Lung cancer 510      (3.5) 480         (3.7) 30           (1.7) <0.001 
Osteoporosis 5,002   (34.0) 4,375     (33.8) 627         (35.6) 0.14 
Rheumatoid arthritis, 
Osteoarthritis 10,293 (70.0) 9,101     (70.3) 1,192      (67.7) 0.021 
Stroke, transient ischemic 
attack 2,991   (20.3) 2,685    (20.8) 306         (17.4) 0.001 
Counties level health care access variables calculated as mean per 10,000 older adults (SE) 
Primary care physicians 55.7   (0.21) 55.6     (0.23) 56.4      (0.62) 0.216 
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Medical specialty 
physicians 72.3   (0.54) 71.8     (0.57) 75.7      (1.52) 0.019 
Allergy immunology 
specialty 1.02   (0.01) 1          (0.01) 1.1        (0.03) 0.042 
Cardiovascular specialty 5.5     (0.04) 5.5       (0.05)  5.8         (0.123) 0.029 
Pulmonary specialty 2.6     (0.02) 2.6       (0.02) 2.7        (0.06) 0.183 
Emergency medicine 
specialty 7.8     (0.05) 7.8       (0.06) 7.9         (0.14) 0.301 
Preventive medicine 
specialty 0.43    (0.01) 0.4     (0.01) 0.4       (0.02) 0.572 
Hospitals number 1.6      (0.01) 1.7     (0.01) 1.6      (0.04) 0.026 
Hospitals with emergency 
department 1.01    (0.01) 1        (0.01)  1         (0.03) 0.427 
Average household size 2.57    (0.002)  2.58   (0.002)   2.56      (0.01) 0.004 
Percent below poverty    11.35   (0.04)     11.4    (0.04)   11.2      (0.11) 0.066 
*Variables were compared between the two treatment groups using bivariate analysis (un-adjusted). 
ESRD: End stage renal disease; LABA: long acting beta agonist; LTRA: leukotriene receptor antagonist; 
ICS: inhaled corticosteroids; SE: standard error.   
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4.4.2 Primary Analysis: Treatment Effects (Augmented Inverse Propensity Weighting 
Models) 
Results of the augmented inverse propensity weighting models (Table 4-2) revealed significantly 
increased probabilities of asthma related hospitalizations and/or ED visits with ICS+LTRA 
compared with ICS+LABA (calculated OR: 1.40, p<0.001). Similarly, results showed that 
treatment with ICS+LTRA was associated with a higher probability for exacerbations needing 
OCS or antibiotics (calculated OR: 1.41, p<0.001). SABA fills were significantly greater among 
patients who received ICS+LTRA versus ICS+LABA (RR: 1.58, p<0.001). Treatment change 
and all-cause death were not different between the two treatment groups. On the other hand, our 
results showed that ICS+LTRA is associated with a significantly lower probability for CV 
related hospitalizations/ED visits (calculated OR: 0.86, p=0.006) versus ICS+LABA. After 
excluding patients who died during the study period, the interpretation of our results did not 
change (Table 4-3). The overlap plots showed no evidence that the overlap assumption is 
violated and are displayed in Appendix A: Figure 1. Further, all covariates were well balanced 
after applying propensity score weighting (Appendix A: Table 6). 
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Table 4-2 Primary analysis results: ORs and RRs for asthma, cardiovascular and other outcomes by treatment group:  
ICS + LTRA vs ICS + LABA  
  
OR 
Adjusted 
probability 
LABA add-on 
Adjusted 
probability 
LTRA add-on 
p value Favor 
Effectiveness outcomes 
Asthma Hospitalizations or ED visits 1.4 0.18 0.24 <0.001 LABA 
Asthma related oral corticosteroids or 
antibiotics prescriptions 1.41 0.17 0.22 <0.001 LABA 
Any asthma exacerbation 1.53 0.3 0.4 <0.001 LABA 
SABA use 1.58 (RR) 1.98 (rate) 3.11 (rate) <0.001 LABA 
Cardiovascular safety 
CV hospitalization/ED 0.86 0.44 0.4 0.006 LTRA 
Other outcomes 
Change treatment * 1.1 0.088 0.096 0.279 Neither 
All-cause death * 0.85 0.054 0.046 0.14 Neither 
 
ORs and RRs were calculated based on adjusted probabilities and rates estimated by the augmented inverse propensity weighting estimator. 
Total sample size= 14,702 (1,762 on ICS+LTRA and 12,940 on ICS+LABA). Average follow up periods= 1.06+ 0.47 person years. 
Change treatment: switching to/or adding the other add-on treatment after at least 6 months on the original treatment. 
* Multivariable logistic regression was used due to propensity scores modelling issues. 
Abbreviations: ED: emergency department; SABA: short acting beta agonists; CV: cardiovascular, LABA: long acting beta agonist; LTRA: 
leukotriene receptor antagonist; ICS: inhaled corticosteroids; OR: odds ratio; RR: rate ratio. 
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Table 4-3 Results after excluding patients who died during the study period. ORs and RRs for asthma, cardiovascular  
and other outcomes by treatment group: ICS + LTRA vs ICS + LABA. 
  OR 
Adjusted 
probability 
LABA add-on 
Adjusted 
probability 
LTRA add-on 
p value  Favor 
Effectiveness outcomes 
Asthma Hospitalizations or ED visits 1.36 0.18 0.23 <0.001 LABA 
Asthma related oral corticosteroids or 
antibiotics prescriptions 1.44 0.18 0.24 <0.001 LABA 
Any asthma exacerbation 1.51 0.3 0.4 <0.001 LABA 
SABA use 1.55 (RR) 1.98 (rate) 3.07 (rate) <0.001 LABA 
Cardiovascular safety 
CV hospitalization/ED 0.85 0.41 0.37 0.005 LTRA 
Other outcomes 
Change treatment* 1.096 0.09 0.098 0.313 Neither 
 
ORs and RRs were calculated based on adjusted probabilities and rates estimated by the augmented inverse propensity weighting estimator. 
Total sample size= 13,528 (1,642 on ICS+LTRA and 11,886 on ICS+LABA). Average follow up periods= 1.08 + 0.47 person years. 
Change treatment: switching to/or adding the other add-on treatment after at least 6 months on the original treatment. 
* Multivariable logistic regression was used due to propensity scores modeling issues. 
Abbreviations: ED: emergency department; SABA: short acting beta agonists; CV: cardiovascular, LABA: long acting beta agonist; LTRA: 
leukotriene receptor antagonist; ICS: inhaled corticosteroids; OR: odds ratio; RR: rate ratio. 
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4.4.3 Treatment Effect Modification by Major Comorbidities 
Treatment effects on asthma hospitalization/ED visits and on any asthma exacerbations were 
significantly different by the presence of any of the major CVDs. Likelihood-ratio test results are 
provided in Appendix A: Table 1. In the CVD stratified analysis, the odds ratio of asthma 
hospitalization/ED visits associated with ICS+LTRA versus ICS+LABA was 1.5; p <0.001 for 
patients with CVD and 1.15; p = 0.329 for patients without CVDs. Similarly, odds ratio of any 
asthma exacerbation was attenuated in the absence of CVD (Table 4-4).  
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Table 4-4 Stratified analysis by the presence of cardiovascular disease (CVD). Results are shown for outcome models in which 
treatment effect is different by the presence of CVDs.  
  
With CVD (ischemic heart disease, congestive heart 
failure, myocardial infarction, atrial fibrillation or 
stroke/transient ischemic attack) 
Without CVD  
Sample size 11,544 (ICS+LTRA: 1,265, ICS+LABA: 10,279) 3,158 (ICS+LTRA: 497, ICS+LABA: 2,661) 
 
OR 
Adjusted 
probability 
LABA add-on 
Adjusted 
probability 
LTRA add-
on 
P 
value Favor OR 
Adjusted 
probability 
LABA add-
on 
Adjusted 
probability 
LTRA add-
on 
p 
value Favor 
Asthma Hospitalizations  
or ED visits 1.5 0.19 0.26 <0.001 LABA 1.15 0.16 0.18 0.329 Neither 
Any asthma  
exacerbation 1.59 0.29 0.4 <0.001 LABA 1.24 0.33 0.39 0.043 LABA 
ORs were calculated based on adjusted probabilities estimated by the augmented inverse propensity weighting estimator; ICS + LTRA vs ICS + 
LABA. 
Abbreviations: ED: emergency department; CVD: cardiovascular disease, LABA: long acting beta agonist; LTRA: leukotriene receptor 
antagonist; ICS: inhaled corticosteroids; OR: odds ratio. 
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In the second analysis of CVDs interaction, the odds of asthma hospitalization/ED visits 
associated with ICS+LTRA were significantly higher compared to ICS+LABA in the CHF/AF 
group, however, no significant difference was noticed in the ischemic diseases or in the non-
CVD group. Considering any asthma exacerbation, the odds ratios were significant and favoring 
LABA add-on treatment in both CVD groups (the ischemic diseases and the CHF/AF diseases) 
but not in the non-CVD group (Table 4-5). Likelihood-ratio test results are provided in 
Appendix A: Table 2.  
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Table 4-5 Stratified analysis by the presence of cardiovascular diseases (CVDs). Results are shown for outcome models in 
which treatment effect is different by the presence of CVDs. CVDs were categorized into three levels: no CVD; having 
preexisting ischemic diseases; or having CHF/AF diseases. 
  Without CVD 
Ischemia diseases; ischemic heart disease, 
acute myocardial infarction, or 
stroke/transient ischemic attack 
Congestive heart failure or atrial fibrillation 
diseases (CHF/AF diseases) 
Sample size 3,158 (ICS+LTRA: 497, ICS+LABA: 2,661) 3,404 (ICS+LTRA: 416, ICS+LABA: 2,988) 8140 (ICS+LTRA: 849, ICS+LABA: 7,291) 
 
OR 
Adjusted 
probability 
LABA add-
on 
Adjusted 
probability 
LTRA add-
on 
P value 
OR 
Adjusted 
probability 
LABA add-
on 
Adjusted 
probability 
LTRA add-
on 
P value 
OR 
Adjusted 
probability 
LABA add-
on 
Adjusted 
probability 
LTRA add-
on 
P value 
(Favor) (Favor) (Favor) 
Asthma 
Hospitalizations 
or ED visits 
1.15 0.16 0.18 
0.329 
1.29 0.17 0.2 
0.096 
11.55 0.2 0.27 
<0.001 
(Neither) (Neither) (LABA) 
Any asthma 
exacerbation 1.24 0.33 0.39 
0.043 
1.57 0.3 0.4 
<0.001 
11.56 0.29 0.39 
<0.001 
(LABA) (LABA) (LABA) 
 
ORs were calculated based on adjusted probabilities estimated by the augmented inverse propensity weighting estimator; ICS + LTRA 
vs ICS + LABA.  
Abbreviations: ED: emergency department; CVD: cardiovascular disease, LABA: long acting beta agonist; LTRA: leukotriene 
receptor antagonist; ICS: inhaled corticosteroids; OR: odds ratio. 
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Treatment interaction with the presence of COPD was also significant in determining 
asthma outcomes associated with each treatment. Likelihood-ratio test results are provided in 
Appendix A: Table 3. Testing for treatment effect by the presence of comorbid COPD revealed 
that ICS+LTRA associated asthma hospitalizations/ED visits as well as asthma related oral 
corticosteroids or antibiotics prescriptions were not significantly different from ICS+LABA in 
the absence of COPD. Similarly treatment changes were not significantly different between the 
two groups in the absence of COPD. On the other hand, SABA use was even higher in patients 
receiving ICS+LTRA compared to ICS+LABA in the absence of COPD (Table 4-6). 
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Table 4-6 Stratified analysis by the presence of COPD comorbidity. Results are shown for outcome models in which treatment effect 
is different by the presence of COPD. 
  With COPD Without COPD 
Sample size 11,422 (ICS+LTRA: 1,212, ICS+LABA: 10,210) 3,280 (ICS+LTRA: 550, ICS+LABA: 2,730) 
 
OR 
Adjusted 
probability 
LABA add-on 
Adjusted 
probability 
LTRA add-on 
p value Favor OR 
Adjusted 
probability 
LABA add-on 
Adjusted 
probability 
LTRA add-on 
p value Favor 
Asthma Hospitalizations 
or ED visits 1.5 0.18 0.25 <0.001 LABA 1.15 0.18 0.2 0.305 Neither 
Asthma related oral 
corticosteroids or              
antibiotics prescriptions 
1.5 0.15 0.22 <0.001 LABA 1.13 0.23 0.25 0.29 Neither 
Any asthma exacerbation 1.59 0.29 0.4 <0.001 LABA 1.28 0.34 0.4 0.02 LABA 
SABA use (RR) 1.55 2.14 3.32 <0.001 LABA 1.65 1.44 2.37 <0.001 LABA 
Change treatment* 1.23 0.06 0.07 0.048 LABA 0.82 0.07 0.06 0.267 Neither 
 
ORs were calculated based on adjusted probabilities estimated by the augmented inverse propensity weighting estimator; ICS + LTRA vs ICS + 
LABA.  
 
*Multivariable logistic regression was used due to propensity scores modeling issue (not concave). 
ORs and RRs : ICS + LTRA vs ICS + LABA. 
Abbreviations: ED: emergency department, COPD: chronic obstructive pulmonary disease; ICS: inhaled corticosteroids; LABA: long acting beta 
agonist; LTRA: leukotriene receptor antagonist; OR: odds ratio; RR: rate ratio. 
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Further interactions between treatment and age (80 or older versus 66-79 years old) as 
well as between treatment and ICS strengths (as a proxy for asthma severity) were tested. 
Patients treated with lower ICS strengths (assumed to have milder asthma) were less likely to 
switch away from LTRA compared to patients treated with medium-high ICS strengths (assumed 
to have more severe asthma) who were more likely to switch to or add LABA add-on treatment 
(p = 0.030). No significant interaction was found between treatment and age for all outcomes. 
 
Secondary analysis: The effect of LABA Add-on strength (as a proxy for LABA dose). 
Results are provided in Appendix A: Table 4. 
4.4.4 Sensitivity Analysis (Incident Users Design) 
In comparison to the prevalent users design we used in the primary analysis, in which most 
patients were prevalent users, this analysis included incident users only and showed no 
significant difference between the two treatment groups on any of the outcomes investigated in 
the primary analysis (Table 4-7).  
Patient characteristic and baseline variables comparisons are provided in Appendix A: Table 5. 
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Table 4-7 Incident users’ design. ORs and RRs for asthma, cardiovascular and other outcomes by treatment group:  
ICS + LTRA vs ICS + LABA. 
  OR  CI 
Adjusted 
probability 
LABA add-
on 
Adjusted 
probability 
LTRA 
add-on 
P value Favor 
Effectiveness outcomes       
Asthma Hospitalizations or ED visits 0.88 0.59 - 1.30 0.2 0.18 0.521 Neither 
Asthma related oral corticosteroids or   1.13 0.76 - 1.67 0.16 0.17 0.548 Neither 
Any asthma exacerbation 0.93 0.66 - 1.31 0.34 0.33 0.665 Neither 
SABA use (RR) 0.93 0.84 - 1.02 2.23 2.06 0.105 Neither 
Cardiovascular safety       
CV hospitalization/ED 1.08 0.75 - 1.56 0.44 0.46 0.661 Neither 
Other outcomes       
All-cause death 0.63 0.31 - 1.27 0.05 0.03 0.198 Neither 
 
Multivariable logistic regression/ Poisson regression were used and were adjusted for all covariates mentioned above. 
Total sample size= 1,338 (184 on ICS+LTRA and 1,154 on ICS+LABA).  
Average follow up periods = 0.98 + 0.51 person years. 
Abbreviations: ED: emergency department; SABA: short acting beta agonists; CV: cardiovascular, LABA: long acting beta agonist; LTRA: 
leukotriene receptor antagonist; ICS: inhaled corticosteroids; OR: odds ratio; RR: rate ratio. 
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4.4.5 Sensitivity Analysis (Discontinuation Design) 
In agreement with primary analysis, results for the discontinuation design showed that patients 
receiving LTRA add-on treatment were more likely to have asthma related hospitalizations/ED 
and asthma related OCS/antibiotic (calculated ORs were 1.29 and 1.3 respectively with p<0.05).  
However, treatment change was significantly lower in patient treated with ICS+LTRA compared 
to ICS+LABA (OR= 0.61, p= 0.047). Adjusted SABA prescription rates were significantly 
higher with ICS+LTRA (calculated RR =1.85, p<0.001). Similar to results from the main 
analysis, LTRA add-on treatment was associated with lower odds of CV related 
hospitalizations/ED visits (calculated OR: 0.8, p = 0.004) (Table 4-8). 
The follow up periods after applying the discontinuation design were on average 39.8% 
and 33.3% of the original follow up periods (primary analysis) for ICS+LABA and ICS+LTRA, 
respectively. 
After excluding patients who died during the study period, the interpretation of the results 
did not change compared to using the full sample in the discontinuation design analysis (Table 
4-9).  
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Table 4-8 Discontinuation design results. ORs and RRs for asthma, cardiovascular and other 
outcomes by treatment group: ICS + LTRA vs ICS + LABA. 
OR 
Adjusted 
probability 
LABA add-on 
Adjusted 
probability 
LTRA add-on 
p value Favor 
Effectiveness outcomes 
Asthma Hospitalizations or 
ED visits 1.29 0.07 0.09 0.036 LABA 
Asthma related oral 
corticosteroids or 
antibiotics prescriptions 
1.3 0.067 0.085 0.03 LABA 
Any asthma exacerbation 1.34 0.13 0.16 0.001 LABA 
SABA use 1.85 (RR) 0.77 (rate) 1.43 (rate) <0.001 LABA 
Cardiovascular safety 
CV Hospitalizations or ED 
visits 0.8 0.22 0.18 0.004 LTRA 
Other outcomes 
Change treatment* 0.61 0.013 0.008 0.047 LTRA 
All-cause death* 0.88 0.01 0.009 0.612 Neither 
ORs and RRs were calculated based on adjusted probabilities and rates estimated by the augmented 
inverse propensity weighting estimator. 
*Multivariable logistic regression was used due to propensity scores modeling issue (not concave).
Abbreviations: ED: emergency department, SABA: short acting beta agonists; LABA: long acting beta
agonist; LTRA: leukotriene receptor antagonist; CV: cardiovascular; OR: odds ratio; RR: rate ratio.
Change treatment: switching to/or adding the other add-on treatment after at least 6 months on the
original treatment.
Total sample size= 14,366 (1,498 on ICS+LTRA and 12,868 on ICS+LABA).
Average follow up periods = 0.33 + 0.32 person years.
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Table 4-9 Discontinuation design results after excluding patients who died in 2010 
  OR 
Adjusted 
probability 
LABA add-on 
Adjusted 
probability 
LTRA add-on 
p value Favor 
Effectiveness outcomes 
Asthma Hospitalizations or 
ED visits 1.29 0.067 0.085 0.041 LABA 
Asthma related oral 
corticosteroids or 
antibiotics prescriptions 
1.32 0.07 0.09 0.021 LABA 
Any asthma exacerbation 1.35 0.12 0.16 0.001 LABA 
SABA use 1.81 (RR) 0.76 (rate) 1.37 (rate) <0.000 LABA 
Cardiovascular safety 
CV hospitalization/ED 0.82 0.19 0.16 0.014 LTRA 
Other outcomes 
Change treatment* 0.62 0.013 0.008 0.049      LTRA 
ORs and RRs were calculated based on adjusted probabilities and rates estimated by the augmented 
inverse propensity weighting estimator. 
*Multivariable logistic regression was used due to propensity scores modeling issue (not concave). 
Abbreviations: ED: emergency department, SABA: short acting beta agonists; LABA: long acting beta 
agonist; LTRA: leukotriene receptor antagonist; CV: cardiovascular; OR: odds ratio; RR: rate ratio.  Total  
Change treatment: switching to/or adding the other add-on treatment after at least 6 months on the 
original treatment.  
Total sample size= 13,220 (1,396 on ICS+LTRA and 11,824 on ICS+LABA).  
Average follow up periods = 0.33 + 0.3 person years. 
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All other results from the discontinuation design are provided in Appendix B: Tables 1-7. 
Table 1: Discontinuation design: Likelihood-ratio test for adding the interaction between 
treatment group and the presence of preexisting CVD. CVD:  ischemic heart disease, congestive 
heart failure, myocardial infarction, atrial fibrillation or transient ischemic attack. 
Table 2: Discontinuation design: Stratified analysis by the presence of major cardiovascular 
diseases (CVD). Results are shown for outcome models in which treatment effect is different by 
the presence of CVDs. 
Table 3: Discontinuation design: Likelihood-ratio test for adding the interaction between 
treatment group and the presence of preexisting CVD. CVDs were categorized into three levels: 
no CVD; having preexisting ischemic diseases; or having CHF/AF diseases. 
Table 4: Discontinuation design: Likelihood-ratio test for adding the interaction between 
treatment group and the presence of preexisting COPD. 
Table 5: Discontinuation design: Stratified analysis by the presence of COPD. Results are shown 
for outcome models in which treatment effect is different by the presence of COPD.  
Table 6: Discontinuation design: Effect of different LABA add-on strengths versus LTRA add-
on treatment. 
Table 7: Discontinuation design: Incident users’ design. ORs and RRs for asthma, 
cardiovascular and other outcomes by treatment group: ICS + LTRA vs ICS + LABA. 
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4.5 DISCUSSION 
To our knowledge, this analysis of older adults with asthma is the first in evaluating 
effectiveness and CV safety outcomes associated with these most commonly used add-on 
treatments in a representative older adult population. Results showed that although LABA is 
more effective than LTRA in controlling asthma in older adults when added to ICS, patients 
treated with LABA add-on treatment were more likely to have major CV events.  
Regarding effectiveness, results showed that LABA add-on treatment was associated 
with lower likelihood of exacerbations that need hospitalizations or ED visits as well as 
exacerbations treated in an outpatient setting by OCS or antibiotic. Further, LABA was 
associated with lower SABA use, a marker of better asthma symptom control. These results are 
consistent with evidence from previous studies of younger cohorts [60-63]. Tan et al studied 
asthma outcomes in patients aged 18 through 64 years old, and they found that LTRA add-on 
treatment was associated with higher odds of inpatient or ED visits (OR = 1.40; CI=1.13-1.73), 
higher odds of OCS (OR=1.33; CI= 1.23-1.44) and higher SABA utilization [63]. Another 
retrospective study showed that asthma exacerbations were more likely with ICS  + montelukast 
compared with ICS+LABA in adults (18–56 years) initiating asthma controller (OR = 1.4, 1.2–
1.6) [61].  
Our results were robust even after applying the sensitivity discontinuation design. 
Following patients only for periods of continuous supply of treatments as measured by days’ 
supply for their prescriptions, LTRA add-on was associated with a higher probability of asthma 
exacerbation and higher SABA utilizations. However, the odd ratios for asthma exacerbations 
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were attenuated in the discontinuation design but still favoring LABA. This indicates that 
improving adherence to ICS+LTRA (both ICS and LTRA) may improve the associated asthma 
outcomes. Even though treatment change was not different in the primary analysis, it was 
significantly lower with LTRA add-on treatment after applying the discontinuation design.  This 
finding is in contrast to previous research that showed a significantly higher treatment 
satisfaction with ICS+LABA than with ICS+LTRA in adults [95, 96]. Our results suggest that 
older adults who adhere to their prescriptions of both ICS and LTRA are actually more satisfied 
than those who adhere to ICS +LABA treatment. This may be explained in part by the milder 
side effects and simplicity of use (as oral treatment) associated with LTRA in older adults [44]. 
One suggested explanation for the lower effectiveness for ICS+LTRA in controlling 
asthma in older adults is the high prevalence of COPD in older adults with asthma [80]. The 
prevalence of COPD diagnosis among our sample of asthmatic older adults was indeed high, at 
78%. Compared to LABA, LTRA is known to be less effective in treating COPD [114]. The 
effects of LTRA versus LABA add-on treatments on asthma exacerbations were significantly 
different by the presence of COPD comorbidity. The probabilities of asthma exacerbations were 
not significantly different between the two add-on treatments in the absence of COPD. This 
might suggest that LTRA is more effective in controlling asthma in the absence of COPD 
comorbidity than in the presence of COPD. However, since we have only around 3000 patients 
without COPD, further research with a larger COPD free older adult sample size is required to 
confirm such effect.   
Previous research has suggested that LABA might be associated with severe asthma-
related hospitalizations and deaths when given with or without ICS [65-71].  In comparison, our 
results did not show any significant increase in asthma related hospitalizations associated with 
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ICS+LABA compared with ICS+LTRA. However, we were limited in this study by lack of 
availability of cause of death, and whether LABA is associated with higher asthma related deaths 
in older adults remains an important question for future research. 
The other major finding in this study is that ICS+LTRA treatment was associated with 
lower odds of CV hospitalizations/ED visits compared to ICS+LABA. There are no published 
clinical trials designed specifically to measure cardiovascular events as a primary endpoint in 
asthma patients treated with ICS+LABA vs. ICS+LTRA. However, a few studies have reported 
adverse CV outcomes. One meta-analysis of placebo controlled clinical trials found that LABAs 
increased the risk for adverse CV events and death compared to placebo [76]. Although CV 
outcomes were never compared directly between the two add-on treatments, one  meta-analysis 
used mostly unpublished data from five studies with 5163 adults concluded that there was no 
statistically significant difference in the risk of CV events between ICS+LABA and ICS+LTRA 
(RR 1.09, 95% CI 0.77 to 1.53) [96].  In comparison to this review, our results suggest that older 
adults may be more susceptible to CV events with ICS+LABA compared to younger ages. This 
is of concern since HCUPnet 2010 national statistics for older adults (65 to 84 old) showed that 
in-hospital mortality rates associated with CV hospitalizations are much higher than with asthma 
hospitalizations [115]. The lower tendency for CV events associated with LTRA was even lower 
when patients were consistently filling their prescriptions in our discontinuation design. This 
might indicate that the better the adherence for LTRA, the lower the CV risk (cardio-protective 
effect), or might imply that the more exposure for LABA in older adults, the more CV risk 
patients will have.  
Interestingly, stratifying by the presence of major CVDs, ICS+LTRA was associated with 
lower odds for CV exacerbations in the presence and absence of major CVDs. However, 
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ICS+LTRA treatment was less effective in controlling asthma in patients with CVDs. This might 
indicate that CVDs may partially contribute to the worse asthma outcomes associated with 
LTRA. 
In the incident users design, differences in treatment effects were not statistically 
different for all asthma, CV, treatment change and all-cause death outcomes. This may indicate 
that the both LTRA and LABA add-on treatments are equivalent in effectiveness and safety in 
the short term period after the initiation and so the differences between them are relatively long 
term effects that are not prominent early in the treatment. Whether this is a true conclusion or 
whether these non-significant results are simply due to the small sample size in this incident 
users design, need to be investigated using larger sample of incident users. The incident users 
design with enough sample size has some advantages over the primary design in this study that 
includes both incident and prevalent users regardless of the initiation time. Incident users design 
improves internal validity by improving confounder control, and captures earlier events that 
occurred after the start of therapy; only the less susceptible patients remain on each treatment 
[116, 117]. On the other hand, using prevalent user design increases the study size and increases 
the precision in estimates. This is especially important in instances where the number of incident 
users available is limited as in our case.  Further, prevalent users design, as opposed to incident 
users design, can increase the ability to study long-term effects associated with cumulative years 
of exposure. One more advantage of prevalent users design is the generalizability; the estimates 
of incident users design may be more valid (internally), but apply to fewer patients. Requiring all 
patients to be incident users without prior use of maintenance medication may focus 
consideration on patients in the earlier or less severe stages in their natural history [116].  
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In summary, ICS+LABA treatment was associated with lower risk of asthma 
exacerbations but higher risk of CV events compared to ICS+LTRA in older adults. In addition 
to asthma outcomes, CV outcomes are especially important in evaluating asthma treatments in 
older adults compared to younger cohorts. Further subgroup analysis is needed to find out which 
patients may be at highest risk for CV adverse events when treated with LABA add-on treatment. 
In addition, further analyses in incident older adult users would be valuable in capturing early 
treatment effects associated with these add-on treatments. 
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5.0  HEALTH CARE EXPENDITURES IN PATIENTS WHO RECEIVED INHALED 
CORTICOSTEROIDS WITH EITHER LEUKOTRIENE RECEPTOR ANTAGONISTS 
OR LONG ACTING BETA AGONISTS AS A COMBINATION THERAPY IN OLDER 
ADULTS 
 
 
 
 
 
 
 
  
75 
5.1 ABSTRACT  
There is a paucity of literature on the costs of pharmacologic treatments in asthmatic older adults 
who are not well controlled on inhaled corticosteroids. Also, the few studies that are available 
consider only asthma related costs and not the all-cause expenditures. All-cause costs are 
important since the adverse effects from pharmacological treatments can affect other comorbid 
conditions in this susceptible population. Understanding the resource utilization of older adults is 
important to better predict future healthcare expenditures in an aging population. This study was 
designed to compare asthma related and all-cause health care expenditures associated with 
ICS+LTRA and ICS+LABA in asthmatic older adults. This was a retrospective cohort study 
conducted using 2009-2010 Medicare fee-for-service (FFS) medical and pharmacy claims from 
10% random sample of beneficiaries continuously enrolled in Parts A, B, and D in 2009. The 
sample comprised patients aged 66 years and older who were treated exclusively with 
ICS+LABA or ICS+LTRA. Outcomes assessed were asthma related costs (medical, pharmacy 
and total), and all-cause health care costs (medical, pharmacy and total). Multivariable regression 
models with nonparametric bootstrapped standard errors were used to compare all-cause and 
asthma related costs. All models were adjusted for demographics, comorbidities, and county 
level health care access variables in addition to follow up periods in person years. The primary 
analysis included 14,702 patients, of whom 12,940 were treated with ICS+LABA and 1,762 
were treated with ICS+LTRA. The results showed that ICS+LTRA treatment was associated 
with increased asthma related costs compared to ICS+LABA. With a mean of 1.06 person years 
follow up period, adjusted asthma related costs were $4,724 for ICS+LTRA group vs $2,939 for 
ICS+LABA group (p<0.001). Total all-cause costs were not significantly different between 
treatment groups ($68,944 for ICS+LTRA compared with $74,369 for ICS+LABA (p=0.219)).  
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The findings reveal that ICS+LABA treatment was associated with lower asthma related 
expenditures compared to ICS+LTRA. However, the total all-cause costs did not differ between 
the two groups, suggesting that lower asthma related costs might be offset by higher non-asthma 
expenditures for older adults treated with ICS+LABA. 
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5.2 INTRODUCTION 
The financial costs of asthma put a considerable burden on US health care resources. In 2007, it 
was estimated that 1.75 million emergency department (ED) visits and 456,000 hospitalizations 
were asthma-related [118]. Asthma is associated with enormous healthcare expenditures. The 
total annual medical cost for asthma in adults was estimated to be around $18 billion [119].  
Asthma in older adults is more expensive than asthma in adulthood with higher medical 
use and worse outcomes [4, 5, 52, 54, 55, 120-125]. In comparison to younger ages, older adults 
experience higher rates of hospital admission, longer length of hospital stay, higher hospital 
charges, higher number of prescribed medications and a higher number of ED visits [52, 55, 57]. 
Few studies have estimated the direct cost of asthma in older adults with age’s ≥65 year old [52]. 
A study conducted in 1994-1995 showed that asthma total direct costs were double in older 
adults compared to younger patients (average per year $1,490 vs. $773, respectively) [52]. In this 
study, hospital inpatient care, medications and outpatient care were found to account for 54%, 
35% and 7% of direct costs, respectively [52]. This study does not evaluate all-cause costs for 
asthmatic older patients, which is a notable limitation since the adverse effects from 
pharmacological treatment can affect other comorbid conditions in this susceptible population.  
As we previously mentioned, LABA and LTRA are the common add-on treatments 
recommended when asthma symptoms are not well-controlled with low dose ICS. Evidence from 
younger populations showed that asthma-related costs for those treated with ICS+LABA 
compared to ICS+LTRA were significantly lower; however, total all-cause costs were less 
studied [61, 63]. Both asthma-related and all-cause costs associated with recommended 
pharmacologic asthma treatments have not been studied in an older adult population. The current 
study was designed to address these gaps in the literature by evaluating asthma-related and all-
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cause costs associated with the most common add-on treatments in older adult patients with 
persistent asthma. 
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5.3 METHODS 
5.3.1 Data Source 
The data source of this study consisted of health care claims and enrollment data of 2009-2010 
Medicare fee-for-service (FFS) (Parts A and B), Part D prescription drug event (PDE) data, and 
Beneficiary Summary Files (BSF) obtained from the Centers for Medicare and Medicaid 
Services (CMS) for a 10% random sample of beneficiaries continuously enrolled in Parts A, B, 
and D in 2009.  
5.3.2 Study Design 
In this retrospective observational cohort investigation, medical and drug claims data were used 
to compare all-cause and asthma related costs among older adults using ICS + LABA versus ICS 
+ LTRA in an exclusive manner. To be eligible to this study, each patient was required to have at
least 4 months of “wash-in” to eliminate any residual effect from the use of other add-on 
therapies prior to 2009 that could potentially confound results. Follow up periods were started on 
the date of the first prescription for the add-on treatment after the 4 months wash-in period and 
ended by death, switching to/adding the other add-on treatment or the end of the study (Dec 31 
2010).  
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5.3.3 Sample 
The study population consists of eligible Medicare beneficiaries continuously enrolled in FFS 
Medicare Parts A and B with Part D coverage from Jan-1 2009 to Dec-31-2010.  Among these 
beneficiaries, the final sample comprised those who: 1) were 66 years old or more as of Jan 1 
2009, 2)  met criteria for having an asthma diagnosis as of Jan 1 2009, as per the CMS Chronic 
Conditions Data Warehouse’s algorithm for detecting asthma in FFS Medicare beneficiaries 
[103, 104], 3) met the above wash-in criteria for being treated exclusively with ICS+LABA or 
ICS+LTRA between 2009-2010, and 4) USA resident. According to CMS Chronic Conditions 
Data Warehouse’s algorithm for detecting asthma, asthma diagnoses were identified by at least 1 
inpatient, skilled nursing facility (SNF), home health agency (HHA) claim, or 2 hospital 
outpatient (HOP) or carrier claims defined by the International Classification of Diseases, Ninth 
Revision, Clinical Modification (ICD-9-CM) codes for asthma (493.XX). 
5.3.4 Outcomes 
Total all-cause costs were calculated as the sum of total all-cause medical and total all-cause 
pharmacy costs. All-cause medical costs were defined as the total of Medicare payments 
associated with inpatient, outpatient (institutional and non-institutional), skilled nursing facility, 
hospice care, home health agency (HHA) and durable medical equipment for any reason. All-
cause pharmacy costs were defined as the sum of all costs associated with prescription 
medications in part D events file.  
Total asthma related costs were calculated as the sum of asthma related medical and 
pharmacy costs. Asthma-related medical costs included Medicare payments associated with 
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inpatient admissions and ED visits assigned a primary or secondary ICD- 9 code for asthma 
(493.XX). Other costs such as physician visits, laboratory tests medical equipment, hospice, 
HHA and nursing home care were not included due to inadequate specificity in the data to be 
differentiated as asthma-related costs [98].  
Asthma related pharmacy costs were defined as the costs associated with asthma 
prescription medications including LABAs, ICS, ICS+LABA, LTRA, oral corticosteroids (OCS) 
or antibiotics used to treat asthma exacerbations, SABA and other less commonly used asthma 
medications like methylxanthin. Asthma medications were identified using National Drug Codes 
(provided by the Healthcare Effectiveness Data and Information Set (HEDIS)).  
Medical (all-cause and asthma related) health-care spending was defined as the amount 
paid by Medicare; costs paid by other sources were not included. Pharmacy costs were defined as 
the sum of the gross cost of pharmacy prescriptions (all-cause and asthma related).  
5.3.5 Covariates 
In addition to the main explanatory variable (treatment group with either ICS+LABA or 
ICS+LTRA), baseline patient characteristics were adjusted for in the multivariate models, 
including demographics, comorbidities, county level health access variables and other variables 
that might confound the association with outcomes. The Beneficiary Summary File was used to 
extract information about:  patient age (as of Jan-1-2009), patient race/ethnicity (Non-Hispanic 
White, black, Hispanic or others), state of residence, sex, enrollment in the low-income subsidy, 
disability indicator, asthma duration since the first diagnosis in Medicare data and several 
comorbidities. The BSF includes diagnosis indicators for 21 chronic conditions along with the 
dates for their first diagnosis in the Medicare data. In order to be considered as preexisting 
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conditions, the first diagnoses in Medicare data were required to be before the date of starting 
patient follow up. Other covariates included in the model were use of beta blockers as these 
medications may affect asthma outcomes [108], ICS strength at the date of starting follow up as 
a proxy for ICS dose and asthma severity, outpatient doctor visits during the “wash-in” period, 
and prescriber characteristics including number of unique prescribers of asthma medications as 
well as the specialty of the prescriber who accounted for the majority of asthma prescriptions. 
Finally, Medicare data were linked to Health Resource and Services Administration’s (HRSA) 
Area Resource File (ARF) to extract county level health care access variables including number 
of primary care physicians, medical specialty physicians, allergy immunology specialty, CV 
specialty, pulmonary specialty, emergency medicine specialty, preventive medicine specialty, 
hospitals number and hospitals with emergency department. These variables were calculated as 
the number per 10,000 older adult residents for each county. County level rurality/urbanicity, 
average household size and percent below poverty were also included. These covariates were 
selected based on the conceptual model presented in Chapter 3 in which they were organized into 
predisposing, medical need and enabling variables. 
5.3.6 Statistical Analysis 
Primary analysis: 
All analyses were conducted in Stata v13 (StataCorp. 2013. Stata Statistical Software: Release 
13. College Station, TX: StataCorp LP). Bivariate analyses (two-sample t-tests and Wald chi-
square tests) were used to compare the difference in population characteristics between the two 
treatment groups. Unadjusted costs per person year were summarized using descriptive statistics 
for the total sample and by treatment group (ICS+LABA vs. ICS+LTRA users). The group 
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comparisons on costs were tested by Wilcoxon test. Further, unadjusted total drug costs and 
number of prescriptions per person year were calculated for asthma treatment classes (ICS, 
ICS+LABA, LABA, LTRA, OCS, SABA, Antibiotics and others) by treatment groups. 
Nonparametric bootstrap procedures with 1,000 replications were used to compare health 
care costs and asthma related costs between the two groups. Bootstrapping is frequently used 
when evaluating differences in costs. [126-128]. Bootstrapping compares arithmetic means 
without making assumptions about the cost distribution [129, 130]. Further, the nonparametric 
bootstrapping method was shown to be robust for data with large zero mass [131]. Treatment 
group indicator was the main explanatory variable in all models. All other covariates were 
adjusted for as described above. Adjusted predicted costs (or marginal costs) were predicted after 
regression models using the mean values for the other independent variables. 
Sensitivity analysis; Discontinuation design: 
In this analysis, patients’ prescription fills were followed to exclude periods of no treatment 
supply based on the ‘days supply’ field in the Medicare part D event file. Patients were censored 
once they had more than 30 days without a treatment supply for either the ICS or the add-on 
treatment.  
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5.4 RESULTS 
5.4.1 Patient Characteristics/Baseline Comparisons 
The characteristics of the study cohort are summarized in Chapter 4 (Table 4-1). A total of 
14,702 patients met the inclusion criteria, of whom 1,762 were receiving ICS+LTRA and 12,940 
were receiving ICS+LABA in an exclusive manner. The average follow up period across the 
whole sample was 1.06 + 0.47 person years. The mean age of the study cohort was 76.5 years; 
72% were female and 78% were Non-Hispanic Whites. The most common co-morbid conditions 
(among the whole sample) were hypertension (91%), hyperlipidemia (83%), cataracts (77.8) and 
COPD (77.7%). The ICS+LABA group had higher prevalence of comorbid chronic diseases. The 
average number of comorbid chronic diseases per patient was 9 across the entire sample; 9 for 
ICS+LABA group and 8 for ICS+LTRA group. 
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5.4.2 Cost of Care 
Unadjusted costs: 
Average unadjusted all-cause and asthma related costs/person year are summarized in Table 5-1. 
The average total all-cause costs per person year were lower for patients treated with ICS+LTRA 
compared with ICS+LABA group ($60,103 vs. $85,459 respectively), however, asthma related 
costs were higher for patients treated with ICS+LTRA compared with ICS+LABA group ($4,521 
vs $3,324). Similarly, ICS+LTRA treatment was associated with lower all-cause medical costs 
but with higher asthma related medical costs compared with ICS+LABA group. On the other 
hand, both all-cause and asthma related pharmacy costs were higher for patients treated with 
ICS+LTRA. All comparisons were statistically significant (p<0.05).  Unadjusted total drug costs 
and number of prescriptions per person year are depicted in Figure 5-1 and Figure 5-2, 
respectively. LTRA treatment was contributed to the highest cost per person year as well as for 
the highest number of prescriptions per person year. 
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Table 5-1 Primary analysis: all-cause and asthma related expenditures by asthma treatment group 
(Unadjusted costs ($) / person year) 
Total sample 
Cost (95% CI) 
LABA add-on 
Cost (95% CI) 
LTRA add-on 
Cost (95% CI) p value Favor 
Total all-cause costs 
Pharmacy and medical 
82420  
(76707 - 88134) 
85459  
(79058 – 91861) 
60103 
(52269 – 67937) 0.0352 LTRA 
All-cause medical costs 76523  (70831 - 82214) 
79692  
(73315 – 86070) 
53244 
(45446 – 61042) <0.001 LTRA 
All-cause pharmacy costs 5898  (5755 – 6040) 
5767  
(5613 – 5921) 
6859  
(6488 – 7230) <0.001 LABA 
Total asthma related costs 
Pharmacy and medical 
3467  
(3282 – 3653) 
3324  
(3120 – 3528) 
4521  
(4131 – 4912) <0.001 LABA 
Medical (asthma 
inpatients/ED) 
1753  
(1581 – 1925) 
1706  
(1517 – 1896) 
2097  
(1753 – 2442) <0.001 LABA 
Asthma related pharmacy 
costs 
1714  
(1645  - 1783) 
1618  
(1544 – 1691) 
2424  
(2236 – 2612) <0.001 LABA 
ED: emergency department; LABA: long acting beta agonist; LTRA: leukotriene receptor antagonist. 
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Figure 5-1 Unadjusted asthma drug expenditures per person years 
ICS: inhaled corticosteroids; LABA: long acting beta agonist; LTRA: leukotriene receptor antagonist; 
SABA: short acting beta agonists; OCS: oral corticosteroids; ICS+LABA: the inhaled corticosteroids/long 
acting beta agonists combination products (single inhaler) 
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Figure 5-2 Total number of prescriptions filled per person years 
ICS: inhaled corticosteroids; LABA: long acting beta agonist; LTRA: leukotriene receptor antagonist; 
SABA: short acting beta agonists; OCS: oral corticosteroids; ICS+LABA: the inhaled corticosteroids/long 
acting beta agonists combination products (single inhaler) 
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Adjusted regression models: 
All-cause costs  
All-cause total and medical costs were not significantly different between the two treatment 
groups. Total all-cause costs were $74,369 for ICS+LABA and $68,944 for ICS+LTRA group. 
The corresponding values for total medical costs were $68,871for ICS+LBA compared with 
$61,724 for ICS+LTRA. All cause pharmacy costs were significantly higher for patients treated 
with ICS+LTRA ($7,219) compared with ICS+LABA group ($5,497) (p<0.001). All predicted 
costs were calculated over a mean of 1.06 person years follow up (Table 5-2).  
Asthma-related costs 
Compared with ICS+LTRA, treatment with ICS+LABA was associated with significantly lower 
asthma-related total, medical and pharmacy costs. Compared to ICS+LTRA, ICS+LABA 
treatment was associated with total asthma-related cost savings (medical + pharmacy) of $1,785, 
asthma related medical saving of $650 and asthma-related pharmacy cost savings of $1134 
(p<0.01for all comparisons). All predicted costs were calculated over a mean of 1.06 person 
years follow up (Table 5-2).  
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Table 5-2 Primary analysis: all-cause and asthma related expenditures by asthma treatment groups (adjusted costs ($)) 
LABA add-on 
Cost (95% CI) 
LTRA add-on 
Cost (95% CI) Saving p value Favor 
Total all-cause costs Pharmacy 
and medical 
74369  
(70574 - 78164) 
68944  
(60944 - 76943) 0.219 Neither 
All-cause medical costs 68871  (65118 - 72624) 
61724  
(53962 - 69487) 0.1 Neither 
All-cause pharmacy costs 5497  (5393 - 5602) 
7219  
(6928 - 7510) 1722 <0.001 LABA 
Total asthma related costs 
Pharmacy and medical 
2939  
(2832 - 3045) 
4724  
(4342 - 5105) 1785 <0.001 LABA 
Medical (asthma 
inpatients/ED) 
1590  
(1491 - 1688) 
2240  
(1827 - 2654) 650 0.003 LABA 
Asthma related pharmacy 
costs 
1349  
(1325 - 1373) 
2483  
(2402 - 2564) 1134 <0.001 LABA 
All predicted costs were calculated over a mean of 1.06 person years follow up. 
ED: emergency department; LABA: long acting beta agonist; LTRA: leukotriene receptor antagonist. 
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Sensitivity analysis; Discontinuation design 
Results were robust after applying the discontinuation design. Following patients for periods of 
continuous medication supply showed similar findings as in the primary analyses design. 
Compared to ICS+LTRA, ICS+ LABA was associated with similar all-cause total and medical 
costs but with significantly lower all-cause pharmacy costs. Also, ICS+LABA treatment was 
associated with significantly lower asthma total and pharmacy costs, however, asthma related 
medical costs (inpatient/ED visits) were not different between the two groups. All predicted costs 
were calculated using a mean of 0.33 person years follow up (Table 5-3). 
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Table 5-3 Discontinuation design: all-cause and asthma related expenditures by asthma treatment group 
(adjusted costs ($)) 
LABA add-on 
Cost (95% CI) 
LTRA add-on 
Cost (95% CI) Saving p value Favor 
Total all-cause costs 
Pharmacy and medical 
24880  
(23052 - 26709) 
22017  
(18145 - 25888) 0.195 Neither 
All-cause medical costs 22585  (20620 - 24550) 
19114  
(15503 - 22725) 0.087 Neither 
All-cause pharmacy costs 2295  (2237 - 2354) 
2902  
(2711 - 3094) 607 <0.001 LABA 
Total asthma related costs 
Pharmacy and medical 
1220  
(1171 - 1269) 
1657  
(1496 - 1817) 437 <0.001 LABA 
Medical (asthma 
inpatients/ED) 
483 
(439 - 528) 
587 
(428 - 746) 0.217 Neither 
Asthma related pharmacy 
costs 
737 
(727 - 747) 
1070  
(1027 - 1112) 333 <0.001 LABA 
All predicted costs were calculated using a mean of 0.33 person years follow up. 
ED: emergency department; LABA: long acting beta agonist; LTRA: leukotriene receptor antagonist. 
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5.5 DISCUSSION 
Consistent with the findings from Chapter 4 (study #1), which showed that ICS+LABA 
treatment is associated with lower risks of asthma exacerbations, this economic evaluation 
showed that patients treated with ICS+LABA incurred significantly lower asthma related cost 
compared with ICS+LTRA. However, the total all-cause costs were similar between the two 
treatment groups.  
Evaluations of younger populations consistently demonstrate that patients receiving ICS+ 
LTRA incur higher asthma related costs compared with patients receiving ICS+LABA [61-63]. 
Tan et al showed, in a retrospective observational study, that the total asthma related annual costs 
in the ICS+LTRA group was 38% higher than those in the ICS+LABA group (p<0.001) [63]. 
Similarly, Lee et al reported higher adjusted mean total asthma-related costs in patients treated 
with ICS+LTRA compared to ICS+LABA patients ($1223 vs. $873 per year) [61]. In agreement 
with these findings, this study showed that ICS+LTRA cohorts incurred higher asthma related 
medical and prescription expenditures in older adult population. Pharmacy costs were a major 
driver of asthma expenditures and were significantly higher in patients treated with ICS+LTRA 
($2483) compared to ICS+LABA ($1349). Among the various asthma drugs, LTRA (mainly 
montelukast) treatment was the most expensive drug per person year mainly due to the highest 
number of prescriptions (9 per person year). These results agreed with previous evidence from 
younger ages in which asthma drugs cost higher in patients treated with ICS+LTRA than in 
patients treated with ICS+LABA ($987 vs $606, respectively) [62]. Even though the conclusion 
was similar to those reported from younger ages, asthma costs estimates in older adults were 
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much higher compared to those estimated in younger adults [61-63]. Although the outpatient 
care costs were not included in asthma related outcomes, this study showed that total asthma cost 
is at least 3-fold and 2-fold higher than previous estimates [61, 63]. Such large inflation in 
asthma costs clearly support the previous evidence that older asthmatic adults experiencing 
larger economic burden compared with younger ages and accordingly need further attention.   
Very few studies have evaluated all-cause costs in asthmatic adults. Stempel and 
coworkers found that non-elderly patients treated with ICS+LABA incurred significantly lower 
total all-cause cost compared with ICS+LTRA ($3466 ICS+LABA versus $4346 ICS+LTRA per 
year). In comparison, our investigation showed that total all-cause costs were not different 
between the two treatment groups ($74,369 in ICS+LABA group and $68,944 in ICS+LTRA 
group). This suggests that the higher asthma costs associated with ICS+LTRA were compensated 
by lower incurring from other conditions in older adults (adjusted for all preexisting comorbid 
condition and other covariates). This may be explained, at least in part, by the suggested negative 
impact of ICS+LABA on the CV conditions in older adults, as revealed in chapter 4 in which 
results showed that older asthmatic patients treated with ICS+LABA were more likely to have 
CV hospitalization or ED visits compared to patients treated with ICS+LTRA.    
Unsurprisingly, total all-cause estimates were much higher than their corresponding 
values estimated from younger ages [62, 98]. Such high numbers are likely due to the high 
prevalence of multi-morbidity among older adults noted in this study. The average number of 
comorbid conditions across the whole sample was nine chronic diseases per patient. An 
investigation of the Centers for Medicare & Medicaid Services that analyzed differences in 
Medicare Fee-for-Service utilization (Medicare perspective) by beneficiary characteristics 
including chronic conditions found an influential effect of chronic conditions on Medicare 
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payments [132]. The average annual payments for beneficiaries with nine comorbid conditions 
were $57,806 for Part A and $22,404 for Part B in 2010 compared with $10,989 and $9,189, 
respectively, for beneficiaries with four comorbid conditions. 
Finally, this study showed that all-cause prescription drug costs were significantly higher 
in patients treated with ICS+LTRA compared to ICS+LABA. This in part was driven by asthma 
treatments that used approximately 25% of all-cause drug costs in ICS+LABA group and around 
34% of all-cause drug costs in ICS+LTRA group.  
Overall, all-cause and asthma related per-patient direct costs for asthmatic FFS Medicare 
beneficiaries were substantial. ICS+LTRA treatment was associated with higher asthma related 
costs (mainly driven by asthma drugs costs) compared to ICS+LABA, however, the total all-
cause costs were not different between the two groups. Higher expenditures on non-asthma 
health conditions were able to offset saving on asthma condition in older adults treated with 
ICS+LABA.  
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6.0  CONCLUSIONS AND FUTURE DIRECTIONS 
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6.1 OVERVIEW 
The objective of this dissertation research was to examine the comparative effectiveness, CV 
safety and costs associated with ICS+LTRA versus ICS+LABA in older adults. The efforts in 
this dissertation were directed to evaluate the relative benefits and risks associated with each 
add-on treatment. Asthma and CV outcomes were the major outcomes investigated in this 
research to reveal the relative effectiveness in controlling asthma as well as the relative CV 
safety associated with both treatments in older adults. 
The results of this research were presented in two studies in Chapters 4 and 5. The first 
study examined the relative effectiveness, CV safety, changing treatment and all-cause mortality 
between ICS+LABA and ICS+LTRA. The second study examined all-cause and asthma related 
expenditures associated with the two treatments. 
This final chapter summarizes the findings of this research, implications to policy-
makers, study strengths and limitations, and directions for future research. 
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6.2 SUMMARY OF FINDINGS 
In this sample of older Medicare beneficiaries with asthma, results from this dissertation showed 
that ICS+LABA was associated with lower risk of asthma exacerbations but with higher risk of 
CV events compared to ICS+LTRA. This picture was reinforced in the economic evaluation 
conducted in which results showed that the ICS+LABA treated patients incur less asthma related 
expenditures but similar all-cause total expenditures. 
Our findings support the CV concerns that have been associated with LABA in previous 
literature and highlight the verdict that LABA-add on treatment may not be safe in older adults 
due to their susceptibility to CV adverse events. These extra CV risks were shown to be more 
prominent when patients adhere to their prescription fills. This may be explained in part by the 
suggested CV protective effect that had been attributed to LTRA in previous literature. However, 
this research was not designed to test such protective effect; rather, it was designed to test the 
relative CV safety between the two add-on treatments. An alternative explanation may be that 
the higher exposure to LABA, the worse the CV outcomes. Further research with longer follow 
up periods in which patients adhere to their medication or fills is warranted to confirm or assess 
such effects. While differences in CV safety profiles were more prominent in patients who 
adhered to their prescriptions, the relative differences between the two treatments for asthma 
related exacerbations were attenuated but still significant. This may be partially explained by the 
better asthma outcomes in ICS+LTRA treated patients during the periods in which they were 
consistently filling their ICS and LTRA prescriptions compared to periods of less adherence. 
Indeed, ICS+LTRA treated patients were filling their LTRA prescriptions more consistently than 
their ICS prescriptions. This is consistent with previous research suggested that older adults are 
more compliant with oral medication rather than with inhaled medications [133]. 
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Treatment effects on asthma exacerbations were largely modified by the presence of 
preexisting comorbid conditions. LTRA add-on was associated with higher odds of asthma 
exacerbation in the presence of CVDs than in their absence, suggesting that the CVDs contribute 
partially to the worse asthma outcomes associated with LTRA. Similarly, asthma exacerbations 
were more equivalent between the two treatments in the absence of COPD. However, odds of 
CV exacerbations were higher with LABA add-on versus LTRA add-on regardless of CVD or 
COPD comorbid conditions in the primary analysis. 
All-cause and asthma related per-patient direct costs for asthmatic FFS Medicare 
beneficiaries were substantial. ICS+LTRA treatment was associated with higher asthma related 
costs (mainly driven by asthma drugs costs) compared to ICS+LABA, however, the total all-
cause costs were not different between the two groups. Higher expenditures on non-asthma 
health conditions were able to offset saving on asthma condition in older adults treated with 
ICS+LABA. 
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6.3 IMPLICATIONS 
Through our investigation of health outcomes associated with these treatments, we have 
enhanced our knowledge regarding the benefits and risk of asthma treatments in older adults. We 
provided information to clinical decision makers that should help in choosing the treatment 
strategy that can maximize benefits at minimal risks. The results of the current research 
underscore the CV concerns associated with LABA treatment particularly in older adults. CV 
concerns associated with LABA should be carefully considered, especially in the older adult 
population. In-hospital mortality rates associated with CV hospitalizations are much higher than 
with asthma hospitalizations in older adults (Figure 6-1) [115].   
The economic evaluation conducted in this dissertation can also enhance clinical 
decision-making in older adults. Efficient and evidence-based resource allocation in health 
practices is an urgent need in this era of inflated health care prices. Overall, this work along with 
those of future studies expanding upon our findings may lead to more personalized treatment and 
improve health outcomes in older adults with asthma by maximizing the benefits and minimizing 
the risks from asthma treatments. 
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Figure 6-1 In-hospital mortality rates associated with asthma and CV hospitalizations in 
older adults (65 to 84 old). Adapted from [115]. 
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Recommendations 
 Our results support the reported concerns about the safety of LABA+ICS treatment in
older adults with asthma. Accordingly, it should be prescribed with caution and only
when benefits in controlling asthma outweigh the CV risks.
 Improving adherence to both ICS and LTRA can maximize the benefit from LTRA add-
on treatment; however, it is still less effective than ICS+LABA. Better CV safety profile
with acceptable, not necessarily better, effectiveness in controlling asthma might be a
wise decision in some situations.
 According to our findings, benefit/risk ratio favors LTRA add-on treatment in the
absence of COPD. This is mainly because of the equivalent effectiveness in preventing
major asthma exacerbations between the two add-on treatments and the better CV safety
associated with ICS+LABA in these patients. However, this conclusion needs to be
confirmed in larger sample of COPD free patients.
 Similarly, our results indicate that the benefit/risk ratio favors LTRA add-on in the
absence of major CVDs since both treatments were equivalent in preventing major
asthma exacerbations, and ICS+LTRA were associated with better CV safety profiles in
these patients. As the case with COPD comorbidity, this conclusion needs to be assessed
in future research with larger sample of CVD free patients.
 Finally, disease specific exacerbation mortality, patients reported outcomes and subgroup
analyses should be considered in patients with ambiguous benefit/risk ratio like those in
whom ICS+LABA is clearly associated with better asthma outcomes but with worse CV
outcomes.
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6.4 STUDY STRENGTHS AND LIMITATIONS 
This research has several limitations. We were limited by only having claims to measure health 
and economic outcomes and medication exposures. Inherently this conveys several drawbacks 
including: 1) lack of clinical effectiveness measures, such as respiratory function tests and 
patients perceived or reported outcome measures, however, exacerbations resulting in 
hospitalizations or ED visits have the greatest impact on quality of life and impose severe 
emotional and financial stress [134], 2) determining exposures based on prescription drug claims 
cannot guarantee actual usage of the medication, 3) inability to adjust for some important factors 
that might confound the results such as smoking history, obesity and education levels, and 4) 
inability to measure some kinds of costs such as over the counter treatments, indirect and 
intangible costs. Smoking history would only bias the results if there were differences in 
smoking rates between the two treatment groups. Even though this might be possible, we 
accounted for some co-morbidities that are often associated with smoking history such as COPD 
and CVDs. Our primary design in this research includes both incident and prevalent users 
regardless of the initiation time. The main concern in mixing incident and prevalent users is 
obscuring excess harm and those events may occur earlier in the course of therapy; only the less 
susceptible patients remain on each treatment [117]. Similarly, the economic burden at the 
beginning of the treatment may be different years after the initiation. However, using prevalent 
user design increases the sample size, enhances generalizability, increases the precision in 
estimates and enables studying long-term effects associated with cumulative years of exposure. 
Even though we applied incident users design to test the robustness of the result and to evaluate 
early outcomes, we were severely limited in sample size.  
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In the discontinuation design we applied in this research, the average follow up period 
was around 0.33 years. This may be not enough to measure the actual benefits and risks 
associated with the two treatments. Further, the discontinuation design was based on information 
captured from the ‘days supply’ field, which may be inaccurate for inhaled treatments. 
Costs were measured from Medicare perspective and patient out-of-pocket and third 
party expenditures were not included. Hence, this study might underestimate the societal cost of 
asthma. However, Medicare expenditures contribute to more than 20% of all US healthcare 
expenditures [135]. In asthma related expenses, only inpatient, ED visits and drugs were 
included, however, outside of medication expenditures, exacerbations resulting in 
hospitalizations or ED visits were shown to have the greatest economic impact among all sources 
of direct costs [61, 63, 134].   
Finally, the potential confounding by asthma severity is an important limitation in this 
study. In an attempt to partially amend this problem, we adjusted to ICS strength as a proxy for 
asthma severity.  Higher ICS strengths are recommended for patients with greater severity. In 
this study, we were not able to measure the actual doses were taken by patients. However, ICS 
strength may serve as proxy for doses. 
There also are key strengths of this research. First, this research addressed questions that 
were never answered in older adult populations as older adults with chronic diseases are 
systematically excluded from clinical trials. We believe that the paucity of knowledge regarding 
asthma treatments in older adults is a contributing factor to the poor health outcomes in this 
population. Second, the use of fee for service (FFS) Medicare beneficiaries claims data makes 
our results generalizable and representative for the older adult population. FFS enrollees 
accounted for approximately 66% of the total Medicare population in 2010 [136]. Third, in the 
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effectiveness and safety study (Chapter 4), we used the augmented inverse propensity weighting 
estimator to model both the outcome and the treatment probability. This method is considered 
“doubly robust” since only one of the two models must be correctly specified to consistently 
estimate the treatment effects [110]. Finally, this is a large observational cohort study of older 
asthmatic adults in which we accounted for many predisposing, medical need and enabling 
factors that may affect both treatment and health care utilization.  
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6.5 FUTURE DIRECTIONS 
Further subgroup analysis with adequate sample size is needed to find out which patients may be 
at highest risk for CV adverse events when treated with LABA add-on treatment. Similarly, 
subgroup analysis is needed to identify which patients may benefit most from LTRA add-on 
treatment.  
Results from this research indicate that ICS+LTRA may be more effective in controlling 
asthma in the absence of COPD comorbidity. Future studies should include adequate numbers of 
asthmatic older adults without COPD to address this point. 
Future research with adequate sample of incident users would provide valuable 
information regarding early treatment effects associated with these add-on treatments and will 
increase the internal validity of the results.  
Finally, further research expanding on our discontinuation design with longer follow up 
periods is warranted. This is of importance to measure treatment effect in patients compliant with 
filling their prescriptions. In particular, this is crucial to understand weather the inferior 
effectiveness of ICS+LTRA combination in the primary analysis was due to real inferior 
effectiveness of the combination or due to lower compliance with the ICS part of the 
combination.  
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APPENDIX A 
Table 1: Likelihood-ratio test for adding the interaction between treatment group and the 
presence of preexisting CVD. CVD:  ischemic heart disease, congestive heart failure, myocardial 
infarction, atrial fibrillation or stroke/transient ischemic attack. 
Outcome p value 
Effectiveness outcomes 
Asthma Hospitalizations or ED visits 0.009 
Asthma related oral corticosteroid or 
antibiotic prescriptions   0.54 
Any asthma exacerbation 0.02 
SABA use 0.312 
Cardiovascular safety 
CV hospitalization/ED 0.961 
Other outcomes 
Change treatment 0.68 
All-cause death 0.567 
ED: emergency department; CV: cardiovascular; 
SABA: short acting beta agonists. 
Treatment effects on asthma hospitalizations/ED visits and any asthma exacerbation were 
different by the presence of major CVDs. 
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Table 2: Likelihood-ratio test for adding the interaction between treatment group and the 
presence of preexisting CVD. CVDs were categorized into three levels: having no preexisting 
CVD; having preexisting ischemic heart disease, acute myocardial infarction, or stroke/transient 
ischemic attack ( ischemic diseases); and having congestive heart failure or atrial fibrillation 
(CHF/AF diseases). 
Outcome p value 
Effectiveness outcomes 
Asthma Hospitalizations or ED visits 0.028 
Asthma related oral corticosteroid or 
antibiotic prescriptions   0.824 
Any asthma exacerbation 0.064 
SABA use 0.458 
Cardiovascular safety 
CV hospitalization/ED 0.465 
Other outcomes 
Change treatment 0.11 
All-cause death 0.681 
ED: emergency department; CV: cardiovascular; 
SABA: short acting beta agonists. 
Treatment effects on asthma hospitalizations/ED visits and any asthma exacerbation were 
different by the presence of major CVDs (categorized to ischemic diseases and CHF/AF 
diseases) 
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Table 3: Likelihood-ratio test for adding the interaction between treatment group and the 
presence of preexisting COPD.  
   Outcome p value 
Effectiveness outcomes 
Asthma Hospitalizations or ED visits 0.0152 
Asthma related oral corticosteroid or 
antibiotic prescriptions   0.0202 
Any asthma exacerbation 0.0142 
SABA use <0.001 
Cardiovascular safety 
CV hospitalization/ED 0.5124 
Other outcomes 
Change treatment 0.053 
All-cause death 0.4301 
ED: emergency department; CV: cardiovascular; 
SABA: short acting beta agonists. 
Treatment effects were different by the presence of major COPD for asthma hospitalizations/ED 
visits, asthma related oral corticosteroids or antibiotics, SABA use, any asthma exacerbation and 
treatment change. 
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Secondary analysis: The effect of  LABA Add-on strength ( as a proxy for dose). 
Table 4: Effect of different LABA add-on strengths versus LTRA add-on.  
  Low LABA strengths  versus LTRA   
 Medium- high LABA strengths 
versus LTRA  
 
OR  p value Favor 
 
OR  p value Favor 
Effectiveness outcomes        Asthma Hospitalizations or ED 
visits 0.75 <0.000 LABA  0.72 <0.000 LABA 
Asthma related oral corticosteroid 
or antibiotic prescriptions   0.77 0.001 LABA 
 
0.67 <0.000 LABA 
Any asthma exacerbation 0.72 <0.000 LABA  0.631 <0.000 LABA 
SABA use (RR) 0.7 <0.000 LABA  0.66 <0.000 LABA 
Cardiovascular safety        
CV hospitalization/ED 1.07 0.304 Neither  1.13 0.044 LTRA 
Other outcomes        
Change treatment 0.76 0.016 LABA 
 
0.95 0.58 Neither 
All-cause death 1.06 0.645 Neither   1.21 0.089 Neither 
Multivariable logistic regression/ Poisson regression were used and were adjusted for all covariates mentioned in chapter 4. 
Abbreviations: ED: emergency department; SABA: short acting beta agonists; CV: cardiovascular, LABA: long acting beta agonist; LTRA: 
leukotriene receptor antagonist; ICS: inhaled corticosteroids; OR: odds ratio; RR: rate ratio. 
 
 
 
111 
Among the total of 12,940 patients who were receiving the LABA add-on treatment, 3,029 were 
receiving low strengths and 9,911 were receiving medium to high strengths at the time of starting 
the follow up. All LABA add-on strengths were associated with lower odds of asthma 
exacerbations and lower SABA use compared to LTRA add-on. Only medium to high strengths 
LABA add-on were associated with statistically significant higher likelihood of CV events 
compared with LTRA add-on (however, both strength were associated with statistically 
significant higher likelihood of CV events in the discontinuation design Appendix B: Table 6) . 
Further, lower strengths LABA-add-on were associated with lower odds of changing the 
treatment compared with LTRA add-on whereas medium to high strengths LABA did not show 
this effect (Table 4). 
112 
Table 5: incident user design: study population characteristics by total and add-on medication group 
Total sample 
n= 1338 (%) 
LABA add-on      
n= 1154 (%) 
LTRA add-on      
n= 184 (%) 
p value1 
Age 
65-70 270      (20.2) 230      (19.9) 40     (21.7) 0.669 
70-75 347     (25.9) 295     (25.6) 52     (28.3) 
75-80 316      (23.6) 278      (24.1) 38     (20.7) 
80+ 405    (30.3) 351       (30.4)  54      (29.4) 
Female gender 985    (73.6) 842      (73.0) 143   (77.7) 0.174 
Race
Non-Hispanic white 1,044    (78.2) 896    (77.8) 148  (80.9) 0.436 
Black 131      (9.8) 119     (10.3) 12     (6.6) 
Hispanic 91       (6.8) 77      (6.7) 14     (7.7) 
Others 69          (5.2) 60         (5.2) 9   (4.9) 
Geographic region
Northeast 315       (23.5) 267      (23.1) 48     (26.1) 0.037 
Midwest 353      (26.4) 317     (27.5) 36     (19.6) 
South 395       (29.5) 328      (28.4) 67     (36.4) 
West 275       (20.6) 242     (21.0) 33    (17.9) 
Asthma duration
<6 months 71          (5.3) 67       (5.8) 4      (2.2) 0.194 
6-12 months 91        (6.8) 78      (6.8) 13    (7.1) 
1-2 years 147    (11.0) 129    (11.2) 18     (9.8) 
>2 years 1,029     (76.9) 880     (76.3) 149  (81.0) 
Disability 221      (16.5) 203     (17.6) 18     (9.8) 0.008 
Major prescriber specialty asthma drugs
Asthma 298      (22.3) 254     (22.0) 44    (23.9) 0.922 
General 844      (63.1) 729     (63.2) 115    (62.5) 
Non-physician 82      (6.1) 71      (6.2) 11       (6.0) 
Others 114      (8.5) 100     (8.7) 14       (7.6) 
Rural Urban
Metro 1,059    (79.8) 903   (78.9) 156    (85.7) 0.089 
Urban 226      (17.0) 203     (17.7) 23       (12.6) 
Rural 42          (3.2) 39       (3.4) 3       (1.7) 
Low income enrollment 629      (47.0) 559     (48.4) 70    (38.0) 0.009 
Using beta blockers 524     (39.2) 455      (39.4) 69       (37.5) 0.619 
Medium to high ICS strength in the pre-
index period
807   (60.3) 700     (60.7) 107    (58.2) 0.519 
Outpatient physician visits in the pre-
index period. means (SE)
4.0        (0.09) 3.9      (0.1) 4.3      (0.3) 0.101 
Number of unique asthma prescribers
mean (SE)
1.8        (0.02) 1.8      (0.03) 1.7       (0.06) 0.315 
Study population Comorbidities
Alzheimer 239    (17.9) 210   (18.2) 29       (15.8) 0.423 
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Acute myocardial infarction 95    (7.1) 89   (7.7) 6         (3.3) 0.029 
Anemia 888    (66.4)  774   (67.1) 114      (62.0) 0.173 
Atrial fibrillation 288    (21.5) 255   (22.1) 33         (17.9) 0.202 
Cancers (other than lung cancer) 175    (13.1) 152    (13.2) 23        (12.5) 0.802 
Cataract 1,034    (77.3) 891  (77.2) 143     (77.7) 0.879 
Chronic kidney disease (CKD)  
    
No CKD 950  (71.0) 807    (69.9) 143      (77.7) 0.063 
CKD, no ESRD 379     (28.3) 338      (29.3) 41        (22.3) 
 
ESRD 9        (0.7) 9        (0.8) 0            (0) 
 
Chronic obstructive pulmonary disease 1,058  (79.1) 928    (80.4) 130      (70.7) 0.002 
Congestive heart failure 692   (51.7) 608       (52.7) 84         (45.7) 0.076 
Depression 579     (43.3) 497    (43.1) 82        (44.6) 0.703 
Diabetes 582     (43.5) 516    (44.7) 66     (35.9) 0.025 
Glaucoma 375    (28.0) 321      (27.8) 54        (29.4) 0.668 
Hip fracture 69       (5.2) 63         (5.5) 6            (3.3) 0.21 
Hyperlipidemia 1,088  (81.3) 939    (81.4) 149      (81.0) 0.899 
Benign Prostatic Hyperplasia 198    (14.8) 171      (14.8) 27         (14.7) 0.959 
Hypertension 1,211  (90.5) 1,055    (91.4) 156      (84.8) 0.004 
Hypothyroidism 350   (26.2) 294     (25.5) 56     (30.4) 0.155 
Ischemic heart 903 (67.5) 786    (68.1) 117   (63.6) 0.224 
Lung cancer 61   (4.6) 53       (4.6) 8         (4.4) 0.882 
Osteoporosis 460   (34.4) 396     (34.3) 64        (34.8) 0.901 
Rheumatoid arthritis, Osteoarthritis 938 (70.1) 806    (69.8) 132     (71.7) 0.602 
Stroke, transient ischemic attack 262   (19.6) 237   (20.5) 25      (13.6) 0.027 
Counties level health care access variables calculated as mean per 10,000 older adults (SE) 
 
Primary care physicians 57.0  (0.76) 56.6     (0.83) 59.5     (1.91) 0.184 
Medical specialty physicians 78.2   (2.12) 77.2     (2.32) 84.9      (4.91) 0.208 
Allergy immunology specialty 1.1   (0.04) 1.1          (0.04) 1.2        (0.08) 0.438 
Cardiovascular specialty 5.9     (0.17) 5.8       (0.19) 6.5        (0.39) 0.136 
Pulmonary specialty 2.8    (0.08) 2.7      (0.09) 3.0     (0.18) 0.328 
Emergency medicine specialty 8.3     (0.21) 8.2      (0.24) 8.9        (0.45) 0.24 
Preventive medicine specialty 0.47    (0.02) 0.46    (0.02) 0.50      (0.06) 0.589 
Hospitals number 1.6      (0.05) 1.6    (0.05) 1.3     (0.07) 0.026 
Hospitals with emergency department 0.92   (0.03) 0.94     (0.03) 0.79       (0.06) 0.08 
Average household size 2.6   (0.01) 2.6  (0.01) 2.6    (0.02) 0.451 
Percent below poverty 11.2  (0.13) 11.1  (0.14) 11.2    (0.38) 0.858 
 
1 Variables were compared between the two treatment groups using bivariate analysis (un-adjusted). 
ESRD: End stage renal disease; LABA: long acting beta agonist; LTRA: leukotriene receptor antagonist; 
ICS: inhaled corticosteroids; SE: standard error.   
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Table 6: Evaluating covariate balance between the two treatment groups after propensity score 
weighting 
After weighting 
LABA add-on (%) LTRA add-on (%) p value* 
Age 0.42 
65-70 19.6 16.5 
70-75 26.9 31.5 
75-80 23.7 21.1 
80+ 29.8 30.8 
Female gender 72.2 68.9 0.5 
Race 0.36 
Non-
Hispanic      white 77.7 74.7 
Black 8.8 8 
Hispanic 8.4 12.4 
Others 5 4.9 
Geographic region 0.092 
Northeast 21.7 27.4 
Midwest 22.6 18.9 
South 36.2 28.9 
West 19.6 24.9 
Asthma duration 0.37 
<6 months 5.3 4.2 
6-12 months 6.4 5.1 
1-2 years 11.5 13.5 
>2 years 76.8 77.2 
Disability 17 20.3 0.51 
Major prescriber 
specialty asthma 
drugs 
0.46 
           Asthma 19.8 18.6 
General 63.6 67.2 
Non-
physician 6.9 5.9 
Others 9.7 8.4 
Rural Urban 0.23 
Metro 78.6 81.8 
Urban 18.6 16.2 
Rural 2.8 2 
Low income 
enrollment 45.7 49.2 0.43 
Using beta blockers 39.9 36.5 0.36 
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Medium to high 
ICS strength at 
index prescription 
76.4 74.5 0.63 
Outpatients 
physician visits in 
the 4 months wash 
in period Means 
(SE) 
4.68 (0.03) 4.74 (0.28) 0.85 
Number of unique 
asthma prescribers 
Mean (SE) 
1.47 (0.01) 1.48 (0.05) 0.82 
Study population Comorbidities 
Alzheimer 17.9 16.8 0.58 
Acute myocardial 
infarction 7.3 7.7 0.81 
Anemia 67.9 72.8 0.07 
Atrial fibrillation 20.4 22.8 0.63 
Cancers (other than 
lung cancer) 15.4 12.3 0.06 
Cataract 77.8 79.6 0.49 
Chronic kidney 
disease (CKD)  0.34 
No CKD 71.2 67.4 
CKD, no 
ESRD 28 32.1 
ESRD 0.9 0.5 
Chronic obstructive 
pulmonary disease 77.7 80.4 0.19 
Congestive heart 
failure 51.4 53.7 0.59 
Depression 43 45.2 0.61 
Diabetes 45.4 51.1 0.19 
Glaucoma 26.6 25.9 0.81 
Hip fracture 5 8 0.12 
Hyperlipidemia 83.4 83.7 0.92 
Benign Prostatic 
Hyperplasia 15.7 21.1 0.28 
Hypertension 91 92.8 0.06 
Hypothyroidism 27.1 29.6 0.53 
Ischemic heart 68.5 71.7 0.26 
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Lung cancer 3.5 2.7 0.25 
Osteoporosis 34 36.5 0.56 
Rheumatoid 
arthritis, 
Osteoarthritis 
70 67 0.53 
Stroke, transient 
ischemic attack 20.4 19.4 0.69 
Counties level health care access variables calculated as mean per 10,000 
older adults (SE) 
Primary care 
physicians 55.7 (0.2) 59.1(2.5) 0.19 
Medical specialty 
physicians 72.3 (0.59) 80.2 (7.3) 0.28 
Allergy 
immunology 
specialty 
1.0 (0.01) 1.1 (0.1) 0.36 
Cardiovascular 
specialty 5.5 (0. 05) 6.1 (0.6) 0.29 
Pulmonary specialty 2.6 (0.02) 2.8 (0.2) 0.4 
Emergency 
medicine specialty 7.8 (.06) 8.1 (0.3) 0.3 
Preventive medicine 
specialty 0.43 (0.01) 0.5 (0.04) 0.4 
Hospitals number 1.6 (0.01) 1.6 (0.05) 0.14 
Hospitals with 
emergency 
department 
1.0 (0.01) 0.9 (0.05) 0.21 
Average household 
size 2.6 (0.002) 2.5 (0.01) 0.49 
Percent below 
poverty 11.3 (0.04) 10.9 (0.3) 0.21 
1 Variables were compared between the two treatment groups using bivariate analysis (un-adjusted). 
ESRD: End stage renal disease; LABA: long acting beta agonist; LTRA: leukotriene receptor antagonist; 
ICS: inhaled corticosteroids; SE: standard error. 
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Figure 1 The overlap plot displays the estimated densities associated with predicted 
probabilities that an ICS+LABA treated patient is an ICS+LABA treated and an ICS+LTRA 
treated patient is an ICS+LABA treated. In both plots, most of their respective masses are in 
regions in which they overlap each other. Accordingly, there is no evidence that the overlap 
assumption is violated. 
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APPENDIX B 
Table 1: Discontinuation design: Likelihood-ratio test for adding the interaction between 
treatment group and the presence of preexisting CVD. CVD:  ischemic heart disease, congestive 
heart failure, myocardial infarction, atrial fibrillation or stroke/transient ischemic attack. 
 
Outcome p value 
Effectiveness outcomes  
Asthma Hospitalizations or ED visits 0.179 
Asthma related oral corticosteroid or 
antibiotic prescriptions   0.253 
Any asthma exacerbation 0.055 
SABA use 0.050 
Cardiovascular safety  
CV hospitalization/ED 0.33 
Other outcomes  
Change treatment 0.794 
All-cause death 0.551 
ED: emergency department; CV: cardiovascular;  
SABA: short acting beta agonists. 
 
Treatment effects on any asthma exacerbation and SABA use were different (marginally 
significant) by the presence of major CVDs. 
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Table 2: Discontinuation design: Stratified analysis by the presence of major cardiovascular diseases (CVD). Results are 
shown for outcome models in which treatment effect is different by the presence of CVDs. 
  
With CVD ( ischemic heart disease, congestive heart 
failure, myocardial infarction, atrial fibrillation or 
stroke/transient ischemic attack) 
Without CVD 
Sample size 11,301 (ICS+LTRA: 1,077, ICS+LABA: 10,224) 3,065 (ICS+LTRA: 421, ICS+LABA: 2,644) 
 
OR 
Adjusted 
probability 
LABA add-on 
Adjusted 
probability 
LTRA add-on 
p value Favor OR 
Adjusted 
probability 
LABA add-on 
Adjusted 
probability 
LTRA add-
on 
p value Favor 
Any asthma 
exacerbation 1.4 0.13 0.17 0.001 LABA 1.1 0.13 0.14 0.594 Neither 
SABA use (RR) 1.93 0.8 1.54 <0.001 LABA 1.81 0.7 1.25 0.008 LABA 
 
ORs were calculated based on adjusted probabilities estimated by the augmented inverse propensity weighting estimator. 
RRs were calculated based on adjusted rates estimated by the augmented inverse propensity weighting estimator. 
Abbreviations: ED: emergency department; CVD: cardiovascular disease, LABA: long acting beta agonist; LTRA: leukotriene receptor 
antagonist; ICS: inhaled corticosteroids; OR: odds ratio; RR: rate ratio. 
 
 
The odds ratio of any asthma exacerbation (ICS+LTRA vs ICS+LABA) was not statistically significant in the absence of CVD. The 
RR of SABA use (ICS+LTRA vs ICS+LABA) was attenuated but still significant in the absence of CVD. 
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Table 3: Discontinuation design: Likelihood-ratio test for adding the interaction between 
treatment group and the presence of preexisting CVD. CVDs were categorized into three levels: 
having no preexisting CVD; having preexisting ischemic heart disease, acute myocardial 
infarction, or stroke/transient ischemic attack (Ischemic diseases group); and having congestive 
heart failure or atrial fibrillation (CHF/AF group).  
Outcome p value 
Effectiveness outcomes 
Asthma Hospitalizations or ED visits 0.365 
Asthma related oral corticosteroid or 
antibiotic prescriptions   0.358 
Any asthma exacerbation 0.072 
SABA use 0.093 
Cardiovascular safety 
CV hospitalization/ED 0.59 
Other outcomes 
Change treatment 0.92 
All-cause death 0.79 
ED: emergency department; CV: cardiovascular; 
SABA: short acting beta agonists. 
Treatment effects were not different by the presence of major CVDs (categorized into ischemic 
diseases and CHF/AF diseases) for all outcomes. 
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Table 4: Discontinuation design: Likelihood-ratio test for adding the interaction between 
treatment group and the presence of preexisting COPD. 
Outcome p value 
Effectiveness outcomes 
Asthma Hospitalizations or ED visits 0.746 
Asthma related oral corticosteroid or 
antibiotic prescriptions   0.003 
Any asthma exacerbation 0.048 
SABA use <0.001 
Cardiovascular safety 
CV hospitalization/ED 0.016 
Other outcomes 
Change treatment 0.9 
All-cause death 0.88 
ED: emergency department; CV: cardiovascular; 
SABA: short acting beta agonists. 
Treatment effects were different by the presence of COPD for asthma related oral corticosteroids 
or antibiotics, SABA use, any asthma exacerbation and CV hospitalization/ED. 
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Table 5: Discontinuation design: Stratified analysis by the presence of COPD. Results are shown for outcome models in which 
treatment effect is different by the presence of COPD.  
 
  With COPD Without COPD 
Sample size 11,198 (ICS+LTRA: 1,041, ICS+LABA: 10,157) 3,168 (ICS+LTRA: 457, ICS+LABA: 2,711) 
 
OR 
Adjusted 
probability 
LABA add-on 
Adjusted 
probability 
LTRA add-on 
 p value Favor OR 
Adjusted 
probability 
LABA add-
on 
Adjusted 
probability 
LTRA add-
on 
p value Favor 
Asthma related oral 
corticosteroid or antibiotic 
prescriptions   
1.56 0.05 0.07 <0.001 LABA 0.79 0.08 0.06 0.223 Neither 
Any asthma exacerbation 1.43 0.12 0.15 <0.001 LABA 0.96 0.13 0.12 0.787 Neither 
SABA use (RR) 1.65 0.68 1.13 <0.001 LABA 2 0.35 0.71 <0.001 LABA 
CV hospitalization/ED 0.73 0.22 0.17 0.001 LTRA 1.2 0.08 0.09 0.321 Neither 
 
 
Multivariable logistic regression was used due to propensity scores modelling issues (not concave) 
Abbreviations: ED: emergency department, COPD: chronic obstructive pulmonary disease; ICS: inhaled corticosteroids; LABA: long 
acting beta agonist; LTRA: leukotriene receptor antagonist; OR: odds ratio; RR: rate ratio. 
 
ICS+LTRA associated asthma related oral corticosteroids or antibiotics prescriptions as well as any asthma exacerbations were not 
significantly different from those associated with ICS+LABA in the absence of COPD. Further, CV exacerbations were not 
significantly different between the two groups in the absence of COPD. SABA use was even higher in patients treated with 
ICS+LTRA compared to those treated with ICS+LABA in the absence of COPD. 
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Table 6: Discontinuation design: Effect of different LABA add-on strengths versus LTRA add-on. 
  Low LABA strengths   versus LTRA   
Medium- High LABA  strengths  
versus LTRA 
 
OR  p value Favor 
 
OR  p value Favor 
Effectiveness outcomes        
Asthma Hospitalizations 
or ED visits 0.85 0.196 Neither  0.86 0.167 Neither 
Asthma related oral 
corticosteroid or antibiotic 
prescriptions   
0.82 0.105 Neither 
 
0.77 0.014 LABA 
Any asthma exacerbation 0.8 0.02 LABA  0.78 0.002 LABA 
SABA use (RR) 0.58 <0.000 LABA  0.57 <0.000 LABA 
Cardiovascular safety        
CV hospitalization/ED 1.24 0.024 LTRA  1.24 0.01 LTRA 
Other outcomes        
Change treatment 0.95 0.865 Neither 
 
1.8 0.01 LTRA 
All-cause death 1.2 0.563 Neither   1.3 0.642 Neither 
Multivariable logistic regression/ Poisson regression were used and were adjusted for all covariates mentioned above. 
Sample size: Low LABA strengths: 3029; Medium- High LABA strengths: 9839.  
Abbreviations: ED: emergency department; SABA: short acting beta agonists; CV: cardiovascular, LABA: long acting beta agonist; 
LTRA: leukotriene receptor antagonist; ICS: inhaled corticosteroids; OR: odds ratio; RR: rate ratio. 
 
 
Both LABA add-on strengths were associated with significantly lower odds of any asthma exacerbation and treatment change and 
with lower SABA use compared with LTRA add-on. Also, both LABA strengths were associated with significantly higher likelihood 
of CV events compared with LTRA add-on.  
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Table 7: Discontinuation design: Incident users’ design. ORs and RRs for asthma, cardiovascular and  
other outcomes by treatment group: ICS + LTRA vs ICS + LABA. 
  OR  CI 
Adjusted 
probability 
LABA 
add-on 
Adjusted 
probability 
LTRA add-
on 
p value Favor 
Effectiveness outcomes       
Asthma Hospitalizations or ED visits 0.68 0.27 - 1.69 0.08 0.06 0.404 Neither 
Asthma related oral corticosteroid or 
antibiotic prescriptions   1.48 0.61 - 3.56 0.04 0.05 0.385 Neither 
Any asthma exacerbation 1.02 0.52 - 2.01 0.14 0.15 0.952 Neither 
SABA use (RR) 0.82 0.66 - 1.04 0.88 0.73 0.097 Neither 
Cardiovascular safety       
CV hospitalization/ED 0.85 0.45 - 1.62 0.2 0.18 0.63 Neither 
 
Multivariable logistic regression/ Poisson regression were used and were adjusted for all covariates mentioned above. 
Total sample size= 655 (106 on ICS+LTRA and 549       on ICS+LABA).  
Average follow up periods = 0.37+ 0.34 person years. 
Abbreviations: ED: emergency department; SABA: short acting beta agonists; CV: cardiovascular, LABA: long acting beta agonist; 
LTRA: leukotriene receptor antagonist; ICS: inhaled corticosteroids; OR: odds ratio; RR: rate ratio. 
For all cause death; model failed “not concave” 
 
 
Analysis of incident users showed no significant difference for all outcomes between the two treatment groups. 
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